<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        0806210771
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2021
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        Olcontro HCT
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        OLMESARTAN MEDOXOMIL,HYDROCHLOROTHIAZIDE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20,12.5
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Film-coated tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        28
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        24
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        47.95
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="Macleods Pharmaceuticals Limited" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            Macleods Pharmaceuticals Limited
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 540]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            ZIMMO TRADING ESTABLISHMENT
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            Med City Pharma
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        C09DA08
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>Olcontro<sup>&reg; </sup>HCT</strong> contains two active substances, olmesartan medoxomil and hydrochlorothiazide, that are used to treat high blood pressure (hypertension):</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Olmesartan medoxomil is one of a group of medicines called angiotensin II-receptor antagonists. It lowers blood pressure by relaxing the blood vessels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Hydrochlorothiazide is one of a group of medicines called thiazide diuretics (&ldquo;water tablets&rdquo;). It lowers blood pressure by helping the body to get rid of extra fluid by making your kidneys produce more urine.</p><p>You will only be given <strong>Olcontro<sup>&reg; </sup>HCT</strong> if <strong>Oletran<sup>&reg;</sup></strong> (olmesartan medoxomil) alone has not adequately controlled your blood pressure. When given together, the two active substances in <strong>Olcontro<sup>&reg; </sup>HCT</strong> help to lower blood pressure more than if either of them were given alone.</p><p>You may already be taking medicines to treat your high blood pressure, but your doctor may want you to take <strong>Olcontro<sup>&reg; </sup>HCT</strong> to lower it more.</p><p>High blood pressure can be controlled with medicines such as <strong>Olcontro<sup>&reg; </sup>HCT</strong> tablets. Your doctor has probably also recommended that you make some changes in your lifestyle to help lower your blood pressure (for example losing weight, giving up smoking, reducing the amount of alcohol you drink and reducing the amount of salt in your diet). Your doctor may also have urged you to take regular exercise, such as walking or swimming. It is important to follow this advice from your doctor.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are allergic to olmesartan medoxomil or hydrochlorothiazide, or any of the other ingredients of this medicine or substances similar to hydrochlorothiazide (sulfonamides).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are more than 3 months pregnant (It is also better to avoid <strong>Olcontro<sup>&reg; </sup>HCT</strong> in early pregnancy).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have severe kidney problems (<strong>Olcontro<sup>&reg; </sup>HCT </strong>20/12.5mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;If you have kidney problems (all stages of renal impairment) (<strong>Olcontro<sup>&reg; </sup>HCT </strong>40/12.5mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have diabetes or impaired kidney function and you are treated with a blood pressure lowering medicine containing aliskiren.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from low potassium, low sodium, high calcium or high uric acid levels in the blood (with symptoms of gout or kidney stones) that do not get better when treated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer from moderate or severe liver problems or yellowing of the skin and eyes (jaundice) or problems with drainage of the bile from the gallbladder (biliary obstruction e.g. gallstones) (<strong>Olcontro<sup>&reg; </sup>HCT</strong> 40/12.5mg).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you suffer severe liver problems or yellowing of the skin and eyes (jaundice) or problems with drainage of the bile from the gallbladder (biliary obstruction e.g. gallstones) (<strong>Olcontro<sup>&reg; </sup>HCT</strong> 20/12.5mg).</p><p>If you think any of these apply to you, or you are unsure, do not take the tablets. Talk to your doctor first and follow the advice given.</p><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor before using <strong>Olcontro<sup>&reg; </sup>HCT</strong>.</p><p><strong>Before you take the tablets, tell your doctor if you are taking any of the following medicines used to treat high blood pressure: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; An ACE-inhibitor (for example enalapril, lisinopril, ramipril), in particular if you have diabetes-related kidney problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Aliskiren.</p><p>Your doctor may check your kidney function, blood pressure, and the amount of electrolytes (e.g. potassium) in your blood at regular intervals.</p><p><strong>Before you take the tablets, tell your doctor if you have any of the following health problems: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Mild to moderate kidney problems or if you have had a recent kidney transplant.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Liver diseases.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heart failure or problems with your heart valves or heart muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Vomiting (being sick) or diarrhoea which is severe or it goes on for several days.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Treatment with high doses of water tablets (diuretics) or if you are on a low salt diet.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Problems with your adrenal glands (e.g. primary aldosteronism).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diabetes.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lupus erythematosus (an autoimmune disease).</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergies or asthma.</p><p><strong>Contact your doctor if you experience any of the following symptoms:</strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diarrhea that is severe, persistent and causes substantial weight loss. Your doctor may evaluate your symptoms and decide on how to continue your blood pressure medication.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Decrease in vision or eye pain. These could be symptoms of an increase of pressure in your eye and can happen within hours to weeks of taking <strong>Oletran<sup>&reg; </sup>HCT</strong>. This can lead to permanent vision impairment, if not treated.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Your doctor may want to see you more often and do some tests if you have any of these conditions. &nbsp;</p><p><strong>Oletran<sup>&reg; </sup>HCT</strong> may cause a rise in blood fat levels and uric acid levels (the cause of gout &ndash; painful swelling of the joints). Your doctor will probably want to do a blood test from time to time to check these.</p><p>It may change the levels of certain chemicals in your blood called electrolytes. Your doctor will probably want to do a blood test from time to time to check these. Signs of electrolyte changes are: thirst, dryness of the mouth, muscle pain or cramps, tired muscles, low blood pressure (hypotension), feeling weak, sluggish, tired, sleepy or restless, nausea, vomiting, less need to pass urine, a rapid heart rate. Tell your doctor if you notice these symptoms.</p><p>As with any medicine which reduces blood pressure, an excessive drop in blood pressure in patients with blood flow disturbances of the heart or brain could lead to a heart attack or stroke. Your doctor will therefore check your blood pressure carefully.</p><p>If you are due to have tests for parathyroid function, you should stop taking <strong>Olcontro<sup>&reg; </sup>HCT</strong> before these tests are carried out.</p><p>If you are a sports person, this medicine could change the results of an anti-dope test to make it positive.</p><p>You must tell your doctor if you think that you are (or might become) pregnant. <strong>Olcontro<sup>&reg; </sup>HCT</strong> is not recommended in early pregnancy, and must not be taken if you are more than 3 months pregnant, as it may cause serious harm to your baby if used at that stage.</p><p><strong>Children and adolescents </strong></p><p><strong>Olcontro<sup>&reg; </sup>HCT</strong> is not recommended for children and adolescents under the age of 18.</p><p><strong>Other medicines and Olcontro<sup>&reg; </sup>HCT</strong></p><p>Tell your doctor or pharmacist if you are using, have recently used or might use any other medicines.</p><p><strong>In particular, tell your doctor or pharmacist about any of the following: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Other blood pressure lowering medicines (anti-hypertensives), as the effect of <strong>Olcontro<sup>&reg; </sup>HCT</strong> can be increased.</p><p>Your doctor may need to change your dose and/or to take other precautions:</p><p>If you are taking an ACE-inhibitor or aliskiren.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines which may alter the levels of potassium in your blood if used at the same time as <strong>Olcontro<sup>&reg; </sup>HCT</strong>. These include:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Potassium supplements (as well as salt substitutes containing potassium).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Water tablets (diuretics).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Heparin (for thinning the blood).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Laxatives.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Steroids.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Adrenocorticotrophic hormone (ACTH).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Carbenoxolone (a medicine used to treat mouth and stomach ulcers).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Penicillin G sodium (also called benzylpenicillin sodium, an antibiotic).</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain pain killers such as aspirin or salicylates.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Lithium (a medicine used to treat mood swings and some types of depression) used at the same time as <strong>Olcontro<sup>&reg; </sup>HCT</strong> may increase the toxicity of lithium. If you have to take lithium, your doctor will measure your lithium blood levels. &nbsp;</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Non-steroidal anti-inflammatory (NSAIDs) medicines (medicines used to relieve pain, swelling and other symptoms of inflammation, including arthritis) used at the same time as <strong>Olcontro<sup>&reg; </sup>HCT</strong> may increase the risk of kidney failure and the effect of <strong>Olcontro<sup>&reg; </sup>HCT</strong> can be decreased by NSAIDs.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Sleeping tablets, sedatives and anti-depressant medicines, as using these medicines together with <strong>Olcontro<sup>&reg; </sup>HCT</strong> may cause a sudden drop in blood pressure when standing up.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines such as baclofen and tubocurarine, used to relax muscles.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amifostine and some other drugs used to treat cancers, such as cyclophosphamide or methotrexate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colestyramine and colestipol, medicines for lowering blood fat levels.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Colesevelam hydrochloride, a drug that lowers the level of cholesterol in your blood, as the effect of <strong>Olcontro<sup>&reg; </sup>HCT</strong> may be decreased. Your doctor may advise you to take <strong>Olcontro<sup>&reg; </sup>HCT</strong> at least 4 hours before colesevelam hydrochloride.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Anticholinergic agents, such as atropine and biperiden.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Drugs such as thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, amisulpride, pimozide, sultopride, tiapride, droperidol or haloperidol, used to treat certain psychiatric disorders.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain medicines such as quinidine, hydroquinidine, disopyramide, amiodarone, sotalol or digitalis, used to treat heart problems.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as mizolastine, pentamidine, terfenadine, dofetilide, ibutilide or erythromycin injections, which may change the heart rhythm.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Oral anti-diabetic medicines, such as metformin, or insulin, used to lower blood sugar.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Beta-blockers and diazoxide, medicines used to treat high blood pressure or low blood sugar, respectively, as <strong>Olcontro<sup>&reg; </sup>HCT</strong> can enhance their blood-sugar-increasing effect.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Methyldopa, a medicine used to treat high blood pressure.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as noradrenaline, used to increase blood pressure and slow heart rate.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Diphemanil, used to treat a slow heartbeat or reduce sweating.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Medicines such as probenecid, sulfinpyrazone and allopurinol, used to treat gout.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Calcium supplements.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amantadine, an anti-viral drug.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Ciclosporin, a medicine used to stop rejection of organ transplants.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain antibiotics called tetracyclines or sparfloxacin.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Amphotericin, a medicine used to treat fungal infections.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Certain antacids, used to treat too much stomach acid, such as aluminium magnesium hydroxide, as the effect of <strong>Olcontro<sup>&reg; </sup>HCT</strong> can be slightly decreased.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Cisapride, used to increase food movement in the stomach and gut.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Halofantrine, used for malaria.</p><p><strong>Olcontro<sup>&reg; </sup>HCT</strong> <strong>with food and drink </strong></p><p><strong>Olcontro<sup>&reg; </sup>HCT</strong> can be taken with or without food.</p><p>Take care when drinking alcohol while you are taking <strong>Olcontro<sup>&reg; </sup>HCT</strong>, as some people feel faint or dizzy. If this happens to you, do not drink any alcohol.</p><p><strong>Black patients </strong></p><p>As with other similar drugs the blood pressure lowering effect of <strong>Olcontro<sup>&reg; </sup>HCT</strong> is somewhat less in black patients.</p><p><strong>Pregnancy and breast-feeding </strong></p><p><strong>Pregnancy </strong></p><p>You must tell your doctor if you think you are (or might become) pregnant. Your doctor will normally advise you to stop taking <strong>Olcontro<sup>&reg; </sup>HCT</strong> before you become pregnant or as soon as you know you are pregnant and will advise you to take another medicine instead of <strong>Olcontro<sup>&reg; </sup>HCT</strong>. <strong>Olcontro<sup>&reg; </sup>HCT</strong> is not recommended during pregnancy, and must not be taken when more than 3 months pregnant, as it may cause serious harm to your baby if it is used after the third month of pregnancy.</p><p><strong>Breast-feeding </strong></p><p>Tell your doctor if you are breast-feeding or about to start breast-feeding. <strong>Olcontro<sup>&reg; </sup>HCT</strong> is not recommended for mothers who are breast-feeding, and your doctor may choose another treatment for you if you wish to breast-feed.</p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong>Driving and using machines </strong></p><p>You may feel sleepy or dizzy while being treated for your high blood pressure. If this happens, do not drive or use machines until the symptoms wear off. Ask your doctor for advice.</p><p><strong>Olcontro<sup>&reg; </sup>HCT</strong> <strong>contains lactose </strong></p><p>This medicine contains lactose (a type of sugar). If you have been told by your doctor that you have an intolerance to some sugars, contact your doctor before taking this medicine.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor has told you. Check with your doctor or pharmacist if you are not sure.</p><p><strong>Olcontro<sup>&reg; </sup>HCT 20/12.5 mg:</strong></p><p><strong>The recommended dose </strong>is one <strong>Olcontro<sup>&reg; </sup>HCT</strong> 20/12.5 mg tablet a day. However, if your blood pressure is not controlled, your doctor may decide to change your dose to one olmesartan/hydrochlorothiazide 20/25 mg tablet a day.</p><p><strong>Olcontro<sup>&reg; </sup>HCT 40/12.5 mg:</strong></p><p><strong>The recommended dose</strong> is one <strong>Olcontro<sup>&reg; </sup>HCT</strong> 40/12.5 mg tablet a day. However, if your blood pressure is not controlled, your doctor may decide to change your dose to one Olmesartan/hydrochlorothiazide 40/25 mg tablet a day.</p><p>Swallow the tablet with water. If possible, you should take your dose at the same time each day, for example at breakfast time. It is important to continue to take <strong>Olcontro<sup>&reg; </sup>HCT</strong> until your doctor tells you to stop. &nbsp;</p><p><strong>If you take more Olcontro<sup>&reg; </sup>HCT</strong> <strong>than you should </strong></p><p>If you take more tablets than you should, or if a child accidentally swallows one or more, go to your doctor or nearest accident and emergency department immediately and take your medicine pack with you.</p><p><strong>If you forget to take Olcontro<sup>&reg; </sup>HCT</strong></p><p>If you forget to take a dose, take your normal dose on the following day as usual. Do not take a double dose to make up for a forgotten dose.</p><p><strong>If you stop taking Olcontro<sup>&reg; </sup>HCT</strong></p><p>It is important to continue to take <strong>Olcontro<sup>&reg; </sup>HCT</strong> unless your doctor tells you to stop.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist. &nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><p><strong>However, the following two side effects can be serious: </strong></p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; Allergic reactions that may affect the whole body, with swelling of the face, mouth and/or voice box (larynx) together with itching and rash may occur rarely. If this happens, stop taking <strong>Olcontro<sup>&reg; </sup>HCT</strong> and contact your doctor immediately.</p><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <strong>Olcontro<sup>&reg; </sup>HCT</strong> can cause the blood pressure to fall too low in susceptible individuals or as the result of an allergic reaction. Light-headedness or fainting may occur uncommonly. If this happens, stop taking <strong>Olcontro<sup>&reg; </sup>HCT</strong>, contact your doctor immediately and lie down flat.<strong> </strong></p><p><strong>Olcontro<sup>&reg; </sup>HCT</strong> is a combination of two active substances and the following information firstly gives the other side effects reported so far with the combination Olmesartan/hydrochlorothiazide (besides those already mentioned above) and, secondly, those which are known about for the separate active substances.</p><p><strong>These are the other side effects known about so far with Olmesartan/hydrochlorothiazide: </strong></p><p>If these side effects occur, they are often mild and you do not need to stop your treatment.</p><p><strong>Common side effects (may affect up to 1 in 10 people): </strong></p><p>Dizziness, weakness, headache, tiredness, chest pain, swelling of ankles, feet, legs, hands or arms.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><p>Fluttering of the heartbeat (palpitations), rash, eczema, vertigo, cough, indigestion, abdominal pain, nausea, vomiting, diarrhea, muscle cramps and muscular pain, pain in joints, arms and legs, back pain, erection difficulties in men, blood in urine.</p><p><strong>Some changes in blood test results have also been seen uncommonly and include: </strong></p><p>Rise in blood fat levels, rise in blood urea or uric acid, rise in creatinine, rise or decrease in blood potassium levels, rise in blood calcium levels, rise in blood sugar, increase in levels of liver function. Your doctor will know about these from a blood test and will tell you if you need to do anything.</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people): </strong></p><p>Feeling unwell, disturbances in consciousness, skin lumps (wheals), acute kidney failure.</p><p><strong>Some changes in blood test results have also been seen in rare cases and include: </strong></p><p>Rise in blood urea nitrogen, decrease in haemoglobin and haematocrit values. Your doctor will know about these from a blood test and will tell you if you need to do anything.</p><p><strong>Further side effects reported with use of olmesartan medoxomil or hydrochlorothiazide alone, but not with Olmesartan/hydrochlorothiazide</strong> <strong>or in a higher frequency: </strong></p><p><strong>Olmesartan medoxomil: </strong></p><p><strong>Common side effects (may affect up to 1 in 10 people): </strong></p><p>Bronchitis, cough, runny or stuffy nose, sore throat, abdominal pain, indigestion, diarrhea, nausea, gastroenteritis, pain in the joints or bones, back pain, blood in urine, urinary tract infection, flu-like symptoms, pain.</p><p><strong>Some changes in blood test results have also been seen commonly and include: </strong></p><p>Rise in blood fat levels, rise in blood urea or uric acid, increase in levels of liver and muscle function.</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><p>Quick allergic reactions that may affect the whole body and may cause breathing problems as well as a rapid fall of blood pressure that may even lead to fainting (anaphylactic reactions), swelling of the face, angina (pain or uncomfortable feeling in the chest; known as angina pectoris), feeling unwell, allergic skin rash, itching, exanthema (skin eruption), skin lumps (wheals).</p><p><strong>Some changes in blood test results have also been seen uncommonly and include: </strong></p><p>Reduced numbers of a type of blood cell, known as platelets (thrombocytopenia).</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people): </strong></p><p>Impaired kidney function, lack of energy.</p><p><strong>Some changes in blood test results have also been seen rarely and include: </strong></p><p>Increase in blood potassium.</p><p><strong>Hydrochlorothiazide: </strong></p><p><strong>Very common side effects (may affect more than 1 in 10 people): </strong></p><p>Changes in blood results including: Increase in blood fat and uric acid levels.</p><p><strong>Common side effects (may affect up to 1 in 10 people): </strong></p><p>Feeling confused, abdominal pain, stomach upset, bloated feeling, diarrhea, nausea, vomiting, constipation, excretion of glucose into the urine.</p><p><strong>Some changes in blood results have also been seen and include: </strong></p><p>Increase in blood creatinine, urea, calcium and sugar levels, decrease in blood chloride, potassium, magnesium and sodium levels. Increase of serum amylase (hyperamylasaemia).</p><p><strong>Uncommon side effects (may affect up to 1 in 100 people): </strong></p><p>Decreased or loss of appetite, severe difficulty breathing, anaphylactic skin reactions (hypersensitivity reactions), worsening of pre-existing myopia, erythema, skin reactions to light itching, purplish spots or patches on the skin due to small haemorrhages (purpura), skin lumps (wheals).</p><p><strong>Rare side effects (may affect up to 1 in 1,000 people): </strong></p><p>Swollen and sore salivary glands, decreased number of white blood cells, decreased number of blood platelets, anaemia, bone marrow damage, restlessness, feeling &lsquo;down&rsquo; or depressed, problems sleeping, feeling un-interested (apathy), tingling and numbness, fits (convulsions), objects you look at appearing yellow, blurred vision, dry eyes, irregular heartbeat, inflammation of the blood vessels, blood clots (thrombosis or embolism), inflammation of the lung, fluid accumulation in the lungs, inflammation of the pancreas, jaundice, infection in the gall bladder, symptoms of lupus erythematosus such as rash, joint pains and cold hands and fingers, allergic skin reactions, peeling and blistering of the skin, non-infectious inflammation of the kidney (interstitial nephritis), fever, muscle weakness (sometimes causing impaired movement).</p><p><strong>Very rare side effects (may affect up to 1 in 10,000 people): </strong></p><p>Electrolyte disturbance leading to an abnormally depleted level of chloride in the blood (hypochloraemic alkalosis), blockage in the gut (paralytic ileus).</p><p><strong>Not known (frequency cannot be estimated from the available data): </strong></p><p>Decrease in vision or eye pain (possible signs of acute angle-closure glaucoma).</p><p>If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep out of the reach and sight of children.</p><p>Do not use <strong>Olcontro<sup>&reg; </sup>HCT </strong>tablets after the expiry date (EXP) which is stated on the blister and the carton.</p><p>The expiry date refers to the last day of that month.</p><p><strong>Olcontro<sup>&reg; </sup>HCT</strong><strong> </strong>tablets: Store below 30&deg;C.</p><p>Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is olmesartan medoxomil and hydrochlorothiazide.</p><p>The other ingredients are Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate, Hypromellose, talc, titanium dioxide, iron oxide red, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Olcontro® HCT 20/12.5 mg: Reddish- yellow, round, biconvex, film-coated tablets debossed with ‘M 11’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.
Pack size: 28 Film Coated tablets.

Oletran® HCT 40/12.5 mg: Reddish-yellow, oval, biconvex, film-coated tablets debossed with ‘M 13’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.
Pack size: 28 Film Coated tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>MAH:</strong> Med City Pharma - KSA</p><p>Tel: 00966920003288</p><p>Fax: 00966126358138</p><p>Mobile: 00966555786968</p><p>P.O Box: 42512 - Jeddah 21551</p><p>E-mail: MD.admin@Axantia.com</p><p><strong>Manufactured by</strong>: Macleods Pharmaceuticals Limited - India.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Jun. 2021
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p dir="RTL">تحتوي <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>على مادتان فعالتان أولميسارتان ميدوكسوميل و هيدروكلوروثيازيد و تستعمل لعلاج ارتفاع ضغط الدم<strong> </strong>(يعرف ايضاً بفرط ضغط الدم):</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنتمي أولميسارتان ميدوكسوميل<strong> </strong>إلى مجموعة الأدوية التي تعرف بمضادات مستقبلات إنزيم أنجيوتنسين-ǁ. والتي تعمل على خفض ضغط الدم عن طريق إرخاء الأوعية الدموية.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; تنتمي هيدروكلوروثيازيد إلى مجموعة من الأدوية تعرف بمدرات البول الثيازيدية (تعرف أيضا بأقراص الماء). والتي تعمل على خفض ضغط الدم عن طريق مساعدة الجسم على تخلص من سوائل الإضافية وذلك عن طريق حث الكلى على إنتاج المزيد من البول.</p><p dir="RTL">سيتم وصف <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>لك إذا كان <strong>أولكنترو<sup>&reg;</sup></strong> (أولميسارتان ميدوكسوميل) لوحده غير كافي لسيطرة على ضغط دمك. تعمل المدتان الفعالتان معاً في <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>على خفض ضغط الدم بشكل أكثر من عمل &nbsp;كل من المدتان الفعالتان على حدى.</p><p dir="RTL">قد يصف لك طبيبك <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> لخفض ضغط دمك أكثر من الأدوية التي تناولتها لعلاج ارتفاع ضغط دمك.</p><p>من الممكن السيطرة على ارتفاع ضغط الدم عن طريق استعمال أدوية مثل أقراص <strong>أولكنترو<sup>&reg;</sup> إتش سي تي</strong>. من المحتمل أيضا أن يوصي طبيبك بإجراء بعض التغييرات في نمط حياتك للمساعدة في تخفيض ضغط الدم (على سبيل المثال فقدان الوزن، الإقلاع عن التدخين، تقليل كمية الكحول المتناولة وتقليل كمية الملح في الطعام). قد يطلب الطبيب منك أيضا الالتزام بممارسة التمارين الرياضة بشكل منتظم، مثل المشي أو السباحة. من المهم أن تتبع نصائح طبيبك.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>يجب عدم تناول</strong> <strong>أوليتران</strong><strong><sup>&reg;</sup></strong><strong> إتش سي تي في حالات التالية:</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا عانيت من تفاعل تحسسي لأولميسارتان ميدوكسوميل<strong> </strong>&nbsp;أو هيدروكلوروثيازيد أو لأي من مكونات أخرى لهذا الدواء أو مواد مشابهة لهيدروكلوروثيازيد (سلفوناميد).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت حامل وعمر الحمل يزيد عن ثلاثة أشهر. (يفضل أيضا تجنب تناول أقراص <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> خلال الأشهر الثلاث الأولى من الحمل).</p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>إذا<strong> </strong>كنت تعاني من اضطربات حادة في الكلى (<strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> 20/12.5 ملغم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطربات في الكلى (و تشمل&nbsp; جميع مراحل اضطربات الكلى) (<strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> 40/12.5 ملغم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من داء السكري أو قصور في وظيفة الكلى ويتم علاجك باستعمال دواء خافض لضغط الدم يحتوي على أليسكرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من مستوى بوتاسيوم منخفض في الدم، مستوى صوديوم منخفض في الدم، مستوى كالسيوم مرتفع في الدم أو مستوى حمض اليوريك مرتفع في الدم (و كنت تعاني من أعراض النقرس أو حصى كلى) و لم تتحسن هذه حالة عند العلاج.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطربات معتدلة أو حادة في الكبد أو اصفرار الجلد و المنطقة البيضاء في العيون (اليرقان) أو مشاكل متعلقة&nbsp; في إفراز الصفراء من الحويصلة الصفراوية (انسداد صفراوي مثل تكون حصاة في مجاري الصفراء). (<strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> 40/12.5 ملغم).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تعاني من اضطربات حادة في الكبد أو اصفرار الجلد و المنطقة البيضاء في العيون (اليرقان) أو مشاكل متعلقة&nbsp; في إفراز الصفراء من الحويصلة الصفراوية (انسداد صفراوي مثل تكون حصاة في مجاري الصفراء). (<strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> 20/12.5 ملغم).</p><p dir="RTL">إذا كان أي مما ذكر في الأعلى ينطبق عليك أو إذا لم تكن متأكدا،لا تتناول الأقراص. الرجاء استشر طبيبك واتبع نصائحه.</p><p dir="RTL"><strong>الاحتياطات والمحاذير</strong></p><p dir="RTL">تحدث مع&nbsp; طبيبك قبل تناول<strong> </strong><strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong><strong><sup> </sup></strong><strong>.</strong></p><p dir="RTL"><strong>قبل تناول الأقراص، </strong>أخبر طبيبك إذا كنت تتناول أي من الأدوية التالية التي تستعمل لعلاج ارتفاع ضغط الدم:</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أحد مثبطات الإنزيم المحول للأنجيوتنسين (مثل إنالابريل، لزينوبريل، راميبريل)، خاصة إذا كنت تعاني من مشاكل في الكلى المرتبطة بداء السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أليسكرين.</p><p dir="RTL">قد يقوم الطبيب بمراقبة وظائف الكلى، ضغط الدم، وكمية الكهرليات (مثل البوتاسيوم) في الدم على فترات منتظمة.</p><p dir="RTL"><strong>قبل تناول الأقراص، أخبر طبيبك إذا كنت تعاني من أي من المشاكل الصحية التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل خفيفة إلى معتدلة في الكلى أو إذا اجريت مؤخراً عملية زراعة كلى.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمراض في الكبد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور في وظيفة عضلة القلب أو مشاكل في صمامات أو عضلة القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قيء (الشعور بتوعك) أو إسهال بشكل حاد و مستمر لعدة أيام.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كنت تخضع للعلاج باستعمال جرعات عالية من أقراص الماء (مدرات البول) أو إذا كنت تخضع لنظام غذائي قليل الملح.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مشاكل في الغدة الكظرية. (مثل فرط أولي لفرز هرمون الألدوستيرون).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; داء السكري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الذئبة الحمامية (أحدى أمراض الجهاز المناعي ذاتي).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الحساسية أو الربو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا عانيت في السابق من سرطان في الجلد أو عانيت من ظهور آفات جلدية خلال العلاج. قد يسبب العلاج باستعمال هيدروكلوروثيازيد وخاصة إذا استمر لفترة طويلة بجرعات عالية زيادة خطر الإصابة ببعض أنواع سرطانات الجلد و الشفاه (سرطان الجلد غير الميلانيني). تجنب التعرض لأشعة الشمس و الأشعة فوق البنفسجية خلال فترة تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong><strong>.</strong></p><p dir="RTL"><strong>أخبر طبيبك إذا </strong>عانيت <strong>أي من الأعراض التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إسهال حاد، مستمر و أدى إلى فقدان كبير في الوزن. قد يقيم طبيبك الأعراض و يقرر كيفية الاستمرار بأدوية ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قصور بالرؤية أو ألم في العين. قد تكون هذه أحدى أعراض ارتفاع الضغط في العين و قد يحدث خلال ساعات إلى أسابيع من تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي. </strong>إذ لم يعالج قد يؤدي إلى اضطراب دائم&nbsp; في الرؤية.</p><p dir="RTL">إذا عانيت أي من هذه الحالات، قد يريد طبيبك زيارته أكثر و إجراء بعض فحوصات.</p><p dir="RTL">قد يسبب <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>ارتفاع مستوى دهون في الدم<strong> </strong>و ارتفاع مستوى حمض اليوريك في الدم (سبب النقرس - تورم مؤلم في المفاصل). على الأغلب يريد طبيبك اخضاعك لفحص دم من وقت لأخر ليتأكد من هذه مستويات في الدم.</p><p dir="RTL">قد تغير مستوى مواد كميائية محددة في الدم و تسمى شوارد كهرلية. على الأغلب يريد طبيبك اخضاعك لفحص دم من وقت لأخر ليتأكد من مستوى الشوارد الكهرلية في الدم. من علامات تغير مستوى الشوارد الكهرلية في الدم: الشعور بالعطش، جفاف الفم، تشنج و ألم في العضل، تعب في العضلات ، ضغط الدم المنخفض (انخفاض ضغط الدم)، الشعور بالضعف، الشعور بالكسل، الشعور بالتعب، شعور بالنعاس أو الأرق، شعور بالغثيان، القئ، قلة حاجة لتبول، تسارع معدل ضربات القلب. أخبر طبيبك إذا لاحظت هذه الأعراض.</p><p dir="RTL">كما هو الحال مع أي دواء خافض لضغط الدم، قد يؤدي الانخفاض المفرط لضغط الدم عند المرضى الذين يعانون من اضطرابات في تدفق الدم من القلب أو إلى الدماغ إلى نوبة قلبية أو سكتة دماغية. لذلك سيقوم طبيبك بمراقبة ضغط الدم بشكل حذر.</p><p dir="RTL">توقف عن تناول&nbsp;<strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> قبل إجراء فحص وظائف غدة جار الدرقية.</p><p dir="RTL">إذا كنت لاعب رياضي قد تتغير نتيجة فحص المنشطات لتصبح نتيجة إيجابية.</p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين أنك حامل (أو من المحتمل حصول حامل). لا يوصى باستعمال <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>&nbsp;خلال فترة مبكرة من الحمل، و يجب عدم استعماله إذا كان عمر الحمل يزيد عن 3 أشهر، حيث قد يؤدي استعماله في هذه المرحلة إلى حدوث ضرر خطير على الجنين.</p><p dir="RTL"><strong>الأطفال و المراهقون</strong></p><p dir="RTL">لا يوصى باستعمال <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong><strong><sup> </sup></strong>&nbsp;للأطفال و المراهقون الذين تقل أعمارهم عن 18 سنة.</p><p dir="RTL"><strong>أدوية أخرى مع أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي<sup> </sup></strong></p><p dir="RTL">أخبر طبيبك أو الصيدلي إذا كنت تتناول، تناولت مؤخراً أو من الممكن أن تتناول أي أدوية أخرى.</p><p dir="RTL"><strong>بشكل خاص، أخبر طبيبك أو الصيدلي إذا كنت تتناول أي من الأدوية التالية:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية أخرى خافضة لضغط الدم (عوامل مضادة لفرط ضغط الدم)، حيث قد يزيد ذلك من تأثير <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong>. قد يحتاج طبيبك إلى تغيير جرعتك و/أو اتخاذ احتياطات أخرى: إذا كنت تتناول أحد مثبطات الإنزيم المحول للأنجيوتنسين أو أليسكرين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تغير مستوى بوتاسيوم في الدم عند استعمالها بالتزامن مع استعمال&nbsp;<strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> في الوقت نفسه. وتشمل:</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات البوتاسيوم (بدائل الملح المحتوية على البوتاسيوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أقراص الماء (مدرات البول).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الهيبارين (للوقاية من تجلط الدم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية الملينية.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ستيرويد.</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية هرمون المنشط لقشرة الكظرية (ACTH).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كاربينوكسولون (دواء يستعمل لعلاج تقرحات الفم و معدة).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بنسيلين ج صوديوم (مضاد حيوي و يسمى ايضاً ببينزلبينسلين صوديوم).</p><p dir="RTL">-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض مسكنات ألام مثل أسبيرين أو ساليسالات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الليثيوم (دواء يستعمل لعلاج تقلبات المزاج و بعض أنواع الاكتئاب) قد يسبب تناوله بشكل متزامن مع <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> زيادة سمية الليثيوم. إذا كان من الضروري تناول الليثيوم، سيقوم طبيبك بفحص مستوى الليثيوم في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية غير الستيرويدية المضادة للالتهاب (أدوية تستعمل لتخفيف الألم، التوروم وأعراض الالتهاب الأخرى، بما في ذلك التهاب المفاصل) إذا تم تناولها بالتزامن مع <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> قد يزيد ذلك من خطر حدوث قصور في وظيفة الكلى &nbsp;و قد يقلل من تأثير&nbsp;<strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي<sup> </sup></strong>عند استعماله بشكل متزامن مع الأدوية غير الستيرويدية المضادة للالتهاب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تساعد على النوم، أدوية المهدئة ومضادات لاكتئاب عند استعمالها مع <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>قد يسبب هبوط مفاجئ لضغط الدم عند الوقوف.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; بعض الأدوية المرخية للعضلات مثل باكلوفين و توبوكيورارين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; اميفوستن و بعض الأدوية التي تستعمل لعلاج السرطان، مثل ميثوتريكسيت أو سيكلوفوسفاميد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولستيرامين وكوليستيبول أدوية تستعمل لعلاج ارتفاع مستويات الدهون في الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كولسيفلام هيدروكلوريد، دواء يستعمل لخفض مستوى كوليستيرول في دم و من الممكن أن&nbsp; يقلل من تأثير <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong>. لذلك قد ينصح طبيبك تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong><strong><sup>&nbsp;</sup></strong>قبل 4 ساعات على الأقل من تناول كولسيفلام هيدروكلوريد.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; عوامل المضادة للكولين مثل اتروبين و بيبيردين.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية مثل ثيوريدازين، كلوربرومازين، ليڤومبرومازين، تريفلوبيرازين، سياميمازين، سيلبيريد، اميسيلبيريد، بيموزايد، سيلتوبرايد، تيابرايد، دروبيرايدول أو هالوبيرايدول، تستعمل لعلاج اضطربات ذهانية محددة.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية محددة تستعمل لعلاج مشاكل القلب، مثل كوينيدين، هيدروكوينيدين، ديسوبيرامايد، اميودارون، سوتالول أو ديجيتاليس.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي قد تغير نظمية القلب ، مثل ميزولاستين، بينتاميدين، تيرفينادين، دوفيتاليد، أبيتاليد أو حقن يريثروميوسن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية مضادة لداء السكري التي تستعمل لتقليل مستوى سكر في الدم &nbsp;(العوامل التي يتم تناولها عن طريق الفم مثل الميتفورمين أو الإنسولين).</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية حاصرات- بتا (تستعمل لعلاج ضغط الدم المرتفع) و دايازوكسيد (تستعمل لعلاج انخفاض مستوى سكر في الدم) وذلك<strong> أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>يساعد على رفع مستوى سكر<strong> </strong>في الدم<strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ميثل دوبا، دواء يستعمل لعلاج ارتفاع ضغط الدم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية مثل نورادرينالين التي تستعمل لرفع ضغط الدم و تبطئ معدل ضربات القلب.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; ديفيمانل تستعمل لعلاج &nbsp;ضربات قلب البطيئة و يقلل التعرق.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; الأدوية التي تستعمل لعلاج النقرس، مثل ألوبيورينول، بروبينسيد، سلفينبيرازون.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مكملات كالسيوم.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أمانتادين وهو دواء مضاد للڤيروسات.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; سيكلوسبورين، وهو دواء يستعمل في عملية زرع الأعضاء للوقاية من رفض العضو.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; مضادات حيوية محددة مثل تيتراسيكلينز أو سبارفلوكساسن.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; امفوتيرسن دواء يستعمل لعلاج التهاب فطري.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; أدوية محددة من مضادات الحموضة تستعمل لعلاج حموضة مفرطة للمعدة، مثل ألومنيوم مغنيسيوم هيدروكسيد، و ذلك يقل من تأثير<strong> أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>بشكل قليل<strong>.</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; كيسابريد يستعمل لزيادة حركة الطعام في المعدة و أمعاء.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; هالوفانترين يستعمل لعلاج الملاريا.</p><p dir="RTL"><strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي مع الطعام و الشراب:</strong></p><p dir="RTL">من الممكن تناول<strong> </strong><strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي </strong>مع أو بدون تناول طعام.</p><p dir="RTL">توخي الحذر عند شرب الكحول خلال فترة تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> و ذلك قد يسبب شعوربالإغماء أو دوخة عند بعض مرضى، في هذه حالة لا تشرب أي نوع من كحول.</p><p dir="RTL"><strong>المرضى ذوو البشرة السمراء</strong></p><p dir="RTL">كما<strong> </strong>هو الحال مع الأدوية المشابهة إن تأثير <strong>أولكنترو<sup>&reg;</sup></strong> الخافض لضغط الدم يكون أقل عند المريض ذوو البشرة السمراء.</p><p dir="RTL"><strong>الحمل والرضاعة الطبيعية</strong></p><p dir="RTL"><strong>الحمل</strong></p><p dir="RTL">يجب أن تخبري طبيبك إذا كنت تعتقدين بأنك حامل (أو من المحتمل حصول الحمل). سيقوم الطبيب عادة بنصحك بالتوقف عن تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> قبل حصول الحمل أوعند معرفتك بالحمل وسيقوم بنصحك بتناول دواء آخر بدلاً من <strong>أولكنترو<sup> &reg;</sup></strong>. لا يوصى باستعمال <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> خلال الأشهر الثلاث الأولى من الحمل، ويجب عدم استعماله إذا كنت حامل وعمر الحمل يزيد عن 3 أشهر، حيث قد يسبب أذى خطير على الجنين في حال استعماله بعد الشهر الثالث من الحمل.</p><p dir="RTL"><strong>الرضاعة الطبيعية</strong></p><p dir="RTL">أخبري طبيبك إذا كنت مرضعة أو على وشك البدء بالرضاعة الطبيعية. لا يوصى باستعمال <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> للأمهات المرضعات، و قد يختار طبيبك علاج أخر إذا كنت ترغبين في الإرضاع.</p><p dir="RTL">إذا كنت حاملا أو مرضعة، تعتقدين بأنك حامل أو تخطيطين للحمل، استشيري طبيبك أو الصيدليقبل تناول هذا الدواء.</p><p dir="RTL"><strong>القيادة و استخدام الآلات </strong></p><p dir="RTL">قد تشعر بالنعاس أو الدوار خلال فترة علاج ارتفاع ضغط الدم. إذا حصل لك هذا تجنب القيادة استخدام الآلات إلى أن تزول هذه الأعراض. استشر طبيبك.</p><p dir="RTL"><strong>يحتوي أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong><strong> على اللاكتوز</strong>.</p><p dir="RTL">يحتوي هذا الدواء على اللاكتوز (نوع من السكر) إذا أخبرت من قبل الطبيب بأنك تعاني من عدم القدرة على تحمل بعض أنواع السكريات، اتصل مع طبيبك قبل تناول هذا الدواء.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">تناول هذا الدواء دائما كما أخبرك طبيبك. تأكد من طبيبك أو الصيدلي إذا لم تكن متأكدا.</p><p dir="RTL"><strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> <strong>20/12.5 ملغم</strong>:</p><p dir="RTL">الجرعة الموصى بها من <strong>أوليتران</strong><strong><sup>&reg;</sup></strong><strong> إتش سي تي </strong>هي قرص واحد 20/12.5 ملغم مرة واحدة يوميا. لكن، إذا لم يتم السيطرة على ضغط الدم، قد يقرر طبيبك تغيير الجرعة إلى قرص واحد من أولميسارتان/ هيدروكلوروثيازيد 20/25 ملغم مرة واحدة يوميا.</p><p dir="RTL"><strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> <strong>40/12.5 ملغم</strong></p><p dir="RTL">الجرعة الموصى بها من <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> هي قرص واحد 40/12.5 ملغم مرة واحدة يوميا. لكن، إذا لم يتم السيطرة على ضغط الدم، قد يقرر طبيبك تغيير الجرعة إلى قرص واحد من أولميسارتان/ هيدروكلوروثيازيد 40/25 ملغم مرة واحدة يوميا.</p><p dir="RTL">قم بتناول الأقراص مع كمية كافية من الماء. إذا أمكن، قم بتناول الجرعة اليومية في نفس الوقت من كل يوم، على سبيل المثال عند وقت الإفطار. من المهم الاستمرار في تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> ما لم يخبرك طبيبك بالتوقف عن ذلك.</p><p dir="RTL"><strong>إذا قمت بتناول أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي<sup> </sup></strong><strong>أكثر مما يجب </strong></p><p dir="RTL">إذا تناولت أقراص أكثر مما يجب أو تناول طفلك قرص أو أكثر عن طريق الخطأ ، اذهب إلى طبيبك أو أقرب قسم طوارئ فوراً و اصطحب معك عبوة الدواء.</p><p dir="RTL"><strong>إذا نسيت تناول جرعة أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong></p><p dir="RTL">إذا نسيت تناول جرعة، تناول جرعتك المعتادة في اليوم التالي كالمعتاد. لا تتناول جرعة مضاعفة لتعويض الجرعة التي نسيتها.</p><p dir="RTL"><strong>إذا توقفت عن تناول أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong></p><p dir="RTL">من المهم الاستمرار في تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> ما لم يخبرك طبيبك بالتوقف عن ذلك.</p><p dir="RTL">إذا كان لديك أية أسئلة إضافية عن استعمال هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">مثل جميع الأدوية، قد يسبب هذا الدواء آثار جانبية، على الرغم من عدم حدوثها لدى الجميع.</p><p dir="RTL"><strong>&nbsp;و لكن، الآثار الجانبية التالية من محتمل أن تكون خطيرة:</strong></p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; في حالات نادرة تم تسجيل التفاعلات التحسسية التالية التي قد تؤثر على كامل الجسم: قد يحدث تورم في الوجه، الفم و/أو الحنجرة مع حكة و طفح. إذا حصل هذا، توقف عن تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> و اتصل مع طبيبك فوراً.</p><p dir="RTL">&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; قد يتسبب <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong>&nbsp; بشكل غير شائع انخفاض كبير في ضغط الدم عند بعض الأشخاص المعرضين لذلك أو نتيجة لتفاعل تحسسي. هذا قد يسبب دوار أو إغماء. إذا حصل هذا، توقف عن تناول <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong>، و اتصل مع طبيبك فوراً و استلقي بشكل مستقيم.</p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>&nbsp;</strong></p><p dir="RTL"><strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي هي </strong>عبارة عن مزيج من مادتان فعالتان سيتم سرد الآثار الجانبية التالية أولاً عن حالات سجلت كآثار جانبية للمزيج &nbsp;أولميسارتان/ هيدروكلوروثيازيد (من ضمنهم الأثار الجانبية التي ذكرت بالأعلى) و ثانياً الأثار الجانبية المعروفة لكل مادة فعالة على حدى.</p><p dir="RTL"><strong>هنالك أثار جانبية معروفة لحداً ما مصاحبة لاستعمال </strong><strong>أولميسارتان/ هيدروكلوروثيازيد:</strong></p><p dir="RTL">إذا حدثت آثار جانبية، غالبا تكون معتدلة و لا تحتاج التوقف عن تناول العلاج.</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر هذه على ما يتراوح بين 1 من كل 10 مريض):</strong></p><p dir="RTL">الشعور بالدوار ، شعور بالضعف، صداع ، الشعور بالتعب ، آلام في الصدر، تورم الكاحلين، القدمين، الساقين، اليدين أو الذراعين.</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر هذه على ما يتراوح بين 1 من كل 100 مريض):</strong></p><p dir="RTL">رفرفة ضربات القلب (خفقان قلب)، طفح جلدي، إكزيما، شعور بالدوار، السعال، عسر الهضم، ألم في منطقة بطن، شعور بالغثيان، القئ، الإسهال، تشنج وألم في العضلات، ألم في مفاصل، اليدين و الأرجل، ألم في الظهر، صعوبات الإنتصاب عند الرجل، ظهور دم في البول.</p><p dir="RTL"><strong>تم ملاحظة بعض التغيرات </strong><strong>غير شائعة </strong><strong>في نتائج فحص الدم و تشمل ما يلي: </strong></p><p dir="RTL">زيادة مستويات الدهون في الدم، زيادة مستوى حمض اليوريك في الدم أو مستوى اليوريا في الدم، ارتفاع مستوى كرياتنين في الدم، ارتفاع أو انخفاض مستوى البوتاسيوم في الدم، ارتفاع مستوى كالسيوم في الدم، ارتفاع مستوى سكر في الدم، ارتفاع قيم نتائج فحوصات وظائف الكبد في الدم.</p><p dir="RTL">سيعلم طبيبك بهذه التغيرات عن طريق نتائج فحص الدم، و سيعلمك بالإجراءات إذا كنت بحاجة لاتباعها.</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر هذه على ما يتراوح بين 1 من كل 1000 مريض):</strong></p><p dir="RTL">الشعور بتوعك، اضطربات في تركيز، ظهور كتل بارزة عن سطح الجلد (لحبة)، قصور حاد في الكلى.</p><p dir="RTL"><strong>تم ملاحظة بعض التغيرات </strong><strong>النادرة </strong><strong>في نتائج فحص الدم و تشمل ما يلي: </strong></p><p dir="RTL">ارتفاع مستوى نيتروجين يوريا في الدم، انخفاض مستوى هيموغلوبين و نسب خلايا دم في الدم.</p><p dir="RTL">سيعلم الطبيب عن أي تغيرات عن طريق فحص الدم و سوف يعلمك عن الإجراءات التي يجب اتباعها إذا كنت بحاجة.</p><p dir="RTL"><strong>سجلت حالات من آثار الجانبية آخرى مصاحبة لاستعمال أولميسارتان ميدوكسوميل أو استعمال هيدروكلوروثيازيد كل منهما على حدى، ولكن لم تسجل هذه الآثارالجانبية عند استعمال المزيج المكون من أولميسارتان ميدوكسوميل/هيدروكلوروثيازيد أو في شدة تكرار اعلى:</strong></p><p dir="RTL"><strong>أولميسارتان ميدوكسوميل:</strong></p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر هذه على ما يتراوح بين 1 من كل 10 مريض):</strong></p><p dir="RTL">التهاب القصبات الهوائية ، السعال، &nbsp;سيلان أو انسداد الأنف ، التهاب الحلق، ألم في منطقة بطن، عسر الهظم، الإسهال، شعور بالغثيان، والتهاب المعدة والأمعاء، ألم في مفاصل أو في عظام، ألم في الظهر، ظهور دم في البول، التهاب جهاز البولي، ظهور أعراض مصاحبة للأنفلونزا، ألم.</p><p dir="RTL"><strong>تم ملاحظة بعض التغيرات أيضا في نتائج فحص الدم و تشمل ما يلي: </strong></p><p>زيادة مستويات الدهون في الدم (ارتفاع مستوى الدهون الثلاثية في الدم)، زيادة مستوى حمض اليوريك في الدم، ارتفاع مستوى اليوريا في الدم، ارتفاع قيم نتائج فحوصات وظائف الكبد والعضلات في الدم.&nbsp;&nbsp;&nbsp; <strong>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</strong></p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر هذه على ما يتراوح بين 1 من كل 100 مريض):</strong></p><p dir="RTL">تفاعلات تحسسية سريعة التي قد تؤثر على الجسم بالكامل و قد تسبب مشاكل في التنفس وأيضا تسبب انخفاض سريع في ضغط الدم الذي قد يؤدي إلى الإغماء (تفاعلات فرط التحسس)، تورم في الوجه، ذبحة صدرية (ألم أو شعور بعدم الراحة في الصدر).، الشعور بتوعك ، طفح جلدي تحسسي ، حكه، طفح ظاهر (طفح بارز عن سطح الجلد)، ظهور كتل بارزة عن سطح الجلد (لحبة).</p><p dir="RTL"><strong>تم ملاحظة بعض التغيرات غير شائعة في نتائج فحص الدم و تشمل ما يلي:</strong></p><p dir="RTL">تم ملاحظة انخفاض عدد أحد أنواع خلايا الدم في فحصوصات الدم الذي يسمى الصفيحات الدموية (قلة الصفيحات الدموية).</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر هذه على ما يتراوح بين 1 من كل 1000 مريض):</strong></p><p dir="RTL">اضطراب وظائف الكلى، نقصان الطاقة.</p><p dir="RTL">تم ملاحظة أيضا بعض التغيرات نادرة في نتائج فحص الدم. وتشمل ارتفاع مستوى البوتاسيوم.</p><p dir="RTL"><strong>هيدروكلوروثيازيد</strong></p><p dir="RTL"><strong>آثار جانبية شائعة جداً (قد تؤثر هذه على أكثر من 1 من كل 10 مريض):</strong></p><p dir="RTL">تم ملاحظة بعض التغيرات في نتائج فحص الدم و تشمل ما يلي: زيادة مستويات الدهون في الدم، زيادة مستوى حمض اليوريك في الدم</p><p dir="RTL"><strong>آثار جانبية شائعة (قد تؤثر هذه على ما يتراوح بين 1 من كل 10 مريض):</strong></p><p dir="RTL">شعور بالارتباك، ألم في منطقة البطن، اضطراب المعدة، شعور بالانتفاخ، الإسهال، شعور بالغثيان، القئ، الإمساك، طرح جلوكوز في البول.</p><p dir="RTL"><strong>تم ملاحظة بعض التغيرات في نتائج فحص الدم و تشمل ما يلي:</strong></p><p dir="RTL">ارتفاع مستوى كرياتنين، يوريا، كالسيوم و سكر في الدم. انخفاض مستوى كلوريد، بوتاسيوم، مغنيسيوم و صوديوم في الدم. ارتفاع مستوى إنزيم أميلاز في مصل الدم (فرط فرز إنزيم أميلاز).</p><p dir="RTL"><strong>آثار جانبية غير شائعة (قد تؤثر هذه على ما يتراوح بين 1 من كل 100 مريض):</strong></p><p dir="RTL">نقص أو فقدان الشهية، اضطربات حادة في التنفس، تفاعلات تحسسية في جلد (تفاعلات فرط التحسس)، تسؤ حالة قصر النظر عند مرضى الذين يعانون من قصر النظر ، حمامي (احمرار جلد)، تفاعلات جلد إلى حكه خفيفة، بقع ارجوانية اللون أو بقع كبيرة (كلف) في الجلد بسبب نزيف طفيف في جلد (وتسمى رفرفة)، كتل بارزة عن سطح الجلد (لحبة).</p><p dir="RTL"><strong>آثار جانبية نادرة (قد تؤثر هذه على ما يتراوح بين 1 من كل 1000 مريض):</strong></p><p dir="RTL">تورم و التهاب غدة اللعابية، انخفاض عدد خلايا دم البيضاء في الدم، انخفاض عدد صفيحات الدموية في الدم، فقر الدم، تلف نخاع العظمي، شعور بالأرق، شعور بالإحباط أو الاكتئاب، اضطربات بالنوم، شعور بعدم الاهتمام (اللامبالاة)، شعور بالخدرو تنمل، نوبات تشنجات، الأشياء التي تنظر إليها تظهر بالون أصفر، اضطربات بالرؤية، جفاف العين، ضربات قلب غير منتظمة، التهاب الأوعية دموية، جلطة دموية (تجلط أو انسداد دموي)، التهاب الرئة، تجمع السوائل في رئة، التهاب بنكرياس، اليرقان، التهاب المرارة، أعراض الذئبة الحمامية (أحدى أمراض الجهاز المناعي ذاتي) مثل طفح جلدي، ألم بالمفصل، يدان و أصابع باردة، تفاعلات حساسية في جلد، تقشر وتقرح جلد، التهاب غير معدي للكلى (التهاب الكلية الخلالي)، حمى، ضعف بالعضلات (بعض الأحيان تسبب اضطربات في حركة).</p><p dir="RTL"><strong>آثار جانبية نادرة جداً (قد تؤثر هذه على ما يتراوح بين 1 من كل 10000 مريض):</strong></p><p dir="RTL">اضطربات شوارد كهرلية تؤدي إلى استنفاذ بشكل غير طبيعي لمستوى كلوريد في الدم (فرط نقص كلوريد في الدم يؤدي إلى قلاء ارتفاع قاعدية الدم)، انسداد في الأمعاء (انسداد معوي بسبب شلل حركة الأمعاء).</p><p dir="RTL"><strong>آثار جانبية غير معروفة (لا يمكن تقدير تكرار حدوثها من المعلومات المتوفرة):</strong></p><p dir="RTL">نقص النظر أو ألم في عين (من المحتمل أن تكون علامة على زرق انسداد الزاوية حادة). سرطان جلد و الشفاه ( سرطان جلد الاميلانومي).</p><p dir="RTL">إذا &nbsp;حدث أي من الآثار الجانبية أو إذا لاحظت أي آثار جانبية غير مذكورة في هذه النشرة، الرجاء إخبار طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">يحفظ بعيدا عن متناول الأطفال و نظرهم.</p><p dir="RTL">لا تستخدم<strong> </strong>أقراص <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> <strong>&nbsp;</strong>بعد تاريخ انتهاء الصلاحية المذكورعلى الشريط و العلبة الخارجية.</p><p dir="RTL">تاريخ الانتهاء يشير إلى اليوم الأخير من ذلك الشهر.</p><p dir="RTL"><strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> <strong>&nbsp;</strong>أقراص: يحفظ&nbsp; بدرجة حرارة دون 30 &deg;م.</p><p dir="RTL">يجب أن لا يتم التخلص من الأدوية عن طريق مياه الصرف الصحي أو النفايات المنزلية. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبة. وسوف تساعد هذه التدابير في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL">ما هي &nbsp;أقراص <strong>أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> <strong>&nbsp;و ماذا</strong> تحتوي</p><p dir="RTL">المادة الفعالة هي أولميسارتان ميدوكسوميل و هيدروكلوروثيازيد.</p><p dir="RTL">المكونات الأخرى هي لاكتوز احادى الهيدرات، ميكروكريستالين سيليلوز، نشا جلايكولات الصوديوم ، هيدروكسي بروبيل سيليلوز ، ثاني أكسيد السيليكون الغروي ، ستيرات المغنيسيوم، هيبروميلوز، تلك، تيتانيوم ثنائي أوكسيد، أكسيد الحديد أحمر ، ماء نقي.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>أقراص أولكنترو</strong><strong><sup>&reg;</sup></strong><strong> إتش سي تي</strong> <strong>20/12.5 ملغم</strong><strong> </strong>أقراص مغلفة دائرية الشكل ذات لون أصفر محمر، محدبة الوجهين، محفور على أحد الأوجه &quot;M 11&quot;، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستخدام عن طريق الفم.</p><p dir="RTL"><strong><u>حجم العبوة:</u></strong></p><p dir="RTL">28 قرص مغلف.</p><p>&nbsp;</p><p dir="RTL"><strong>أقراص أولكنترو<sup>&reg;</sup></strong><strong> إتش سي تي</strong> <strong>40/12.5 ملغم</strong><strong> </strong>أقراص مغلفة بيضوية الشكل ذات لون أصفر محمر، محدبة الوجهين، محفور على أحد الأوجه &quot;M 13&quot;، معبأة في أشرطة ألومنيوم/ألومنيوم، معدة للاستخدام عن طريق الفم.</p><p dir="RTL"><strong><u>حجم العبوة:</u></strong></p><p>28 قرص مغلف.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p><strong>مالك رخصة التسويق: مدينة الدواء للصناعات الدوائية - المملكة العربية السعودية</strong></p><p>هاتف: 00966920003288</p><p>فاكس: 00966126358138</p><p>جوال: 00966555786968</p><p>ص.ب: 42512 - جده 21551</p><p>بريد الكتروني: MD.admin@Axantia.com</p><p><strong>تصنيع: شركة ماكلويد الدوائية المحدودة - الهند</strong></p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            06/2021
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olcontro® HCT 20/12.5 mg Film Coated Tablets.
Olcontro® HCT 40/12.5 mg Film Coated Tablets.
Olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg Film Coated Tablets.
Olmesartan medoxomil/hydrochlorothiazide 40/12.g mg Film Coated Tablets.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Olcontro® HCT 20/12.5 mg: Each film-coated tablet contains 20 mg olmesartan medoxomil and 12.5 mg hydrochlorothiazide.
Olcontro® HCT 40/12.5 mg: Each film-coated tablet contains 40 mg olmesartan medoxomil and 12.5 mg hydrochlorothiazide

For a full list of excipients: see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Film-coated tablets.

Olcontro® HCT 20/12.5 mg: Reddish- yellow, round, biconvex, film-coated tablets debossed with ‘M 11’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.

Olcontro® HCT 40/12.5 mg: Reddish-yellow, oval, biconvex, film-coated tablets debossed with ‘M 13’ on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Treatment of essential hypertension.</p><p><strong>Olcontro<sup>&reg;</sup> HCT </strong>fixed dose combination is indicated in adult patients whose blood pressure is not adequately controlled on olmesartan medoxomil alone.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Posology</u></strong></p><p><strong><em>Adults</em></strong></p><p><strong>Olcontro<sup>&reg;</sup> HCT 20/12.5mg:</strong></p><p><strong>Olcontro<sup>&reg;</sup> HCT</strong> is not for use as initial therapy, but in patients whose blood pressure is not adequately controlled by 20 mg olmesartan medoxomil alone. <strong>Olcontro<sup>&reg;</sup> HCT</strong> is administered once daily, with or without food.</p><p>When clinically appropriate, direct change from monotherapy with 20 mg olmesartan medoxomil to the fixed combination may be considered, taking into account that the<strong>&nbsp;</strong>antihypertensive effect of olmesartan medoxomil is maximal by about 8 weeks after initiating therapy (see section 5.1). Dose titration of the individual components is recommended:</p><p>20 mg olmesartan medoxomil/12.5 mg hydrochlorothiazide may be administered in patients whose blood pressure is not adequately controlled by the optimal monotherapy olmesartan medoxomil 20 mg alone.</p><p>20 mg olmesartan medoxomil/ 25 mg hydrochlorothiazide may be administered in patients whose blood pressure is not adequately controlled by 20 mg olmesartan medoxomil/ 12.5 mg hydrochlorothiazide.</p><p><strong>Olcontro<sup>&reg;</sup> HCT 40/12.5mg:</strong></p><p>The recommended dose of <strong>Olcontro<sup>&reg;</sup> HCT </strong>40/12.5 mg is 1 tablet per day.</p><p><strong>Olcontro<sup>&reg;</sup> HCT </strong>40/12.5 mg may be administered in patients whose blood pressure is not adequately controlled by olmesartan medoxomil 40 mg alone.</p><p>Olmesartan medoxomil/hydrochlorothiazide 40/25 mg may be administered in patients whose blood pressure is not adequately controlled on <strong>Olcontro<sup>&reg;</sup> HCT </strong>40/12.5 mg fixed dose combination.</p><p>For convenience, patients receiving olmesartan medoxomil and hydrochlorothiazide from separate tablets may be switched to <strong>Olcontro<sup>&reg;</sup> HCT</strong> 40/12.5 mg tablets containing the same component doses.</p><p><strong>Olcontro<sup>&reg;</sup> HCT </strong>40/12.5 mg can be taken with or without food.</p><p><strong><em>Elderly (age 65 years or over)</em></strong></p><p>In elderly people the same dosage of the combination is recommended as for adults.</p><p>Blood pressure should be closely monitored.</p><p><strong><em>Renal impairment</em></strong></p><p>When <strong>Olcontro<sup>&reg;</sup> HCT</strong> is used in patients with mild to moderate renal impairment (creatinine clearance of 30-60 mL/min) periodic monitoring of renal function is advised (see section 4.4). <strong>Olcontro<sup>&reg;</sup> HCT</strong> 20/12.5 mg is contraindicated in patients with severe renal impairment (creatinine clearance &lt;30 mL/min) (see section 4.3).</p><p>The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 30-60 mL/min) is 20 mg olmesartan medoxomil once daily, owing to limited experience of higher dosages in this patient group, and periodic monitoring is advised.</p><p><strong>Olcontro<sup>&reg;</sup> HCT </strong>40/12.5 mg is therefore contraindicated in all stages of renal impairment (see sections 4.3, 4.4, 5.2).</p><p><strong><em>Hepatic impairment</em></strong></p><p><strong>Olcontro<sup>&reg;</sup> HCT</strong> 20/12.5 mg should be used with caution in patients with mild to moderate hepatic impairment (see sections 4.4, 5.2). In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily.</p><p>Close monitoring of blood pressure and renal function is advised in hepatically-impaired patients who are receiving diuretics and/or other antihypertensive agents. There is no experience of olmesartan medoxomil in patients with severe hepatic impairment.</p><p><strong>Olcontro<sup>&reg;</sup> HCT </strong>20/12.5 mg should not be used in patients with severe hepatic impairment (see sections 4.3, 5.2), cholestasis and biliary obstruction (see section 4.3).</p><p><strong>Olcontro<sup>&reg;</sup> HCT</strong> 40/12.5 mg should be used with caution in patients with mild hepatic impairment (see sections 4.4, 5.2). There is no experience of olmesartan medoxomil in patients with severe hepatic impairment. <strong>Olcontro<sup>&reg;</sup> HCT </strong>40/12.5 mg therefore should not be used in patients with moderate and severe hepatic impairment (see sections 4.3, 5.2), as well as in cholestasis and biliary obstruction (see section 4.3).</p><p><strong><em>Paediatric population</em></strong></p><p>The safety and efficacy of <strong>Olcontro<sup>&reg;</sup> HCT</strong> in children and adolescents below 18 years has not been established. No data are available.</p><p><strong><u>Method of administration</u></strong></p><p>The tablet should be swallowed with a sufficient amount of fluid (e.g. one glass of water). The tablet should not be chewed and should be taken at the same time each day.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substances, to any of the excipients listed in section 6.1 or to other sulfonamide-derived substances (since hydrochlorothiazide is a sulfonamide-derived medicinal product).
Olcontro® HCT 20/12.5 mg is contraindicated in patients with severe renal impairment (creatinine clearance <30 mL/min).
Olcontro® HCT 40/12.5 mg is contraindicated in all stages of renal impairment.
Refractory hypokalaemia, hypercalcaemia, hyponatraemia and symptomatic hyperuricaemia.
Olcontro® HCT 20/12.5 mg is contraindicated in patients with severe hepatic impairment, as well as in cholestasis and biliary obstruction.
Olcontro® HCT 40/12.5 mg is contraindicated in patients with moderate and severe hepatic impairment, as well as in cholestasis and biliary obstruction.
2nd and 3rd trimester of pregnancy (see sections 4.4 and 4.6).
The concomitant use of Olcontro® HCT with aliskiren-containing products is contraindicated in patients with diabetes mellitus or renal impairment (GFR <60 mL/min/1.73 m2) (see sections 4.5 and 5.1).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Intravascular volume depletion:</strong></p><p>Symptomatic hypotension, especially after the first dose, may occur in patients who are volume and/or sodium depleted by vigorous diuretic therapy, dietary salt restriction, diarrhea or vomiting. Such conditions should be corrected before the administration of <strong>Olcontro<sup>&reg;</sup> HCT</strong>.</p><p><strong>Other conditions with stimulation of the renin-angiotensin-aldosterone system:</strong></p><p>In patients whose vascular tone and renal function depend predominantly on the activity of the renin-angiotensin-aldosterone system (e.g. patients with severe congestive heart failure or underlying renal disease, including renal artery stenosis), treatment with medicinal products that affect this system has been associated with acute hypotension, azotaemia, oliguria or, rarely, acute renal failure.</p><p><strong>Renovascular hypertension:</strong></p><p>There is an increased risk of severe hypotension and renal insufficiency when patients with bilateral renal artery stenosis or stenosis of the artery to a single functioning kidney are treated with medicinal products that affect the renin-angiotensin-aldosterone system.</p><p><strong>Renal impairment and kidney transplantation:</strong></p><p><strong>Olcontro<sup>&reg;</sup> HCT</strong> 20/12.5mg should not be used in patients with severe renal impairment (creatinine clearance &lt;30 mL/min) (see section 4.3). No dosage adjustment is necessary in patients with mild to moderate renal impairment (creatinine clearance is &ge;30 mL/min, &lt;60 mL/min). However, in such patients <strong>Olcontro<sup>&reg;</sup> HCT</strong> should be administered with caution and periodic monitoring of serum potassium, creatinine and uric acid levels is recommended. Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function. If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration given to discontinuing diuretic therapy.</p><p>The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 30-60 mL/min) is 20 mg olmesartan medoxomil once daily. However, in such patients <strong>Olcontro<sup>&reg;</sup> HCT</strong> 20/12.5 mg should be administered with caution and periodic monitoring of serum potassium, creatinine and uric acid levels is recommended. Thiazide diuretic-associated azotaemia may occur in patients with impaired renal function. If progressive renal impairment becomes evident, careful reappraisal of therapy is necessary, with consideration given to discontinuing diuretic therapy.</p><p><strong>Olcontro<sup>&reg;</sup> HCT</strong> 40/12.5 mg is therefore contraindicated in all stages of renal impairment (see section 4.3).</p><p>There is no experience of the administration of <strong>Olcontro<sup>&reg;</sup> HCT</strong> in patients with a recent kidney transplantation.</p><p><strong>Dual blockade of the renin-angiotensin-aldosterone system (RAAS):</strong></p><p>There is evidence that the concomitant use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren increases the risk of hypotension, hyperkalaemia and decreased renal function (including acute renal failure). Dual blockade of RAAS through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is therefore not recommended (see sections 4.5 and 5.1).</p><p>If dual blockade therapy is considered absolutely necessary, this should only occur under specialist supervision and subject to frequent close monitoring of renal function, electrolytes and blood pressure.</p><p>ACE-inhibitors and angiotensin II receptor blockers should not be used concomitantly in patients with diabetic nephropathy.</p><p><strong>Hepatic impairment:</strong></p><p>There is currently no experience of olmesartan medoxomil in patients with severe hepatic impairment. In patients with moderate hepatic impairment, the maximum dose is 20 mg olmesartan medoxomil.</p><p>Furthermore, minor alterations of fluid and electrolyte balance during thiazide therapy may precipitate hepatic coma in patients with impaired hepatic function or progressive liver disease.</p><p>Therefore care should be taken in patients with mild to moderate hepatic impairment (see section 4.2). Use of <strong>Olcontro<sup>&reg;</sup> HCT</strong> 20/12.5mg in patients with severe hepatic impairment, cholestasis and biliary obstruction is contraindicated (see sections 4.3, 5.2).</p><p>Therefore the use of <strong>Olcontro<sup>&reg;</sup> HCT</strong> 40/12.5 mg in patients with moderate and severe hepatic impairment, cholestasis and biliary obstruction is contraindicated (see sections 4.3, 5.2). Care should be taken in patients with mild impairment (see section 4.2).</p><p><strong>Aortic and mitral valve stenosis, obstructive hypertrophic cardiomyopathy:</strong></p><p>As with other vasodilators, special caution is indicated in patients suffering from aortic or mitral stenosis, or obstructive hypertrophic cardiomyopathy.</p><p><strong>Primary aldosteronism:</strong></p><p>Patients with primary aldosteronism generally will not respond to anti-hypertensive medicinal products acting through inhibition of the renin-angiotensin system. Therefore, the use of <strong>Olcontro<sup>&reg;</sup> HCT</strong> is not recommended in such patients.</p><p><strong>Metabolic and endocrine effects:</strong></p><p>Thiazide therapy may impair glucose tolerance. In diabetic patients dosage adjustments of insulin or oral hypoglycaemic agents may be required (see section 4.5). Latent diabetes mellitus may become manifest during thiazide therapy.</p><p>Increases in cholesterol and triglyceride levels are undesirable effects known to be associated with thiazide diuretic therapy.</p><p>Hyperuricaemia may occur or frank gout may be precipitated in some patients receiving thiazide therapy.</p><p><strong>Electrolyte imbalance:</strong></p><p>As for any patient receiving diuretic therapy, periodic determination of serum electrolytes should be performed at appropriate intervals.</p><p>Thiazides, including hydrochlorothiazide, can cause fluid or electrolyte imbalance (including hypokalaemia, hyponatraemia and hypochloraemic alkalosis). Warning signs of fluid or electrolyte imbalance are dryness of the mouth, thirst, weakness, lethargy, drowsiness, restlessness, muscle pain or cramps, muscular fatigue, hypotension, oliguria, tachycardia, and gastrointestinal disturbances such as nausea or vomiting (see section 4.8).</p><p>The risk of hypokalaemia is greatest in patients with cirrhosis of the liver, in patients experiencing brisk diuresis, in patients who are receiving inadequate oral intake of electrolytes and in patients receiving concomitant therapy with corticosteroids or ACTH (see section 4.5).</p><p>Conversely, due to antagonism at the angiotensin-II receptors (AT<sub>1</sub>) through the olmesartan medoxomil component of <strong>Olcontro<sup>&reg;</sup> HCT</strong> hyperkalaemia may occur, especially in the presence of renal impairment and/or heart failure, and diabetes mellitus. Adequate monitoring of serum potassium in patients at risk is recommended. Potassium-sparing diuretics, potassium supplements or potassium-containing salt substitutes and other medicinal products that may increase serum potassium levels (e.g. heparin) should be co-administered cautiously with <strong>Olcontro<sup>&reg;</sup> HCT</strong> (see section 4.5).</p><p>There is no evidence that olmesartan medoxomil would reduce or prevent diuretic-induced hyponatraemia. Chloride deficit is generally mild and usually does not require treatment.</p><p>Thiazides may decrease urinary calcium excretion and cause an intermittent and slight elevation of serum calcium in the absence of known disorders of calcium metabolism. Hypercalcaemia may be evidence of hidden hyperparathyroidism. Thiazides should be discontinued before carrying out tests for parathyroid function.</p><p>Thiazides have been shown to increase the urinary excretion of magnesium, which may result in hypomagnesaemia.</p><p>Dilutional hyponatraemia may occur in oedematous patients in hot weather.</p><p><strong>Lithium:</strong></p><p>As with other medicinal products containing angiotensin II receptor antagonists and thiazide in combination, the coadministration of <strong>Olcontro<sup>&reg;</sup> HCT</strong> and lithium is not recommended (see section 4.5).</p><p><strong>Sprue-like enteropathy:</strong></p><p>In very rare cases severe, chronic diarrhea with substantial weight loss has been reported in patients taking olmesartan few months to years after drug initiation, possibly caused by a localized delayed hypersensitivity reaction. Intestinal biopsies of patients often demonstrated villous atrophy. If a patient develops these symptoms during treatment with olmesartan, and in the absence of other apparent etiologies, olmesartan treatment should be immediately discontinued and should not be restarted. If diarrhoea does not improve during the week after the discontinuation, further specialist (e.g. a gastro-enterologist) advice should be considered.</p><p><strong>Acute Myopia and Secondary Angle-Closure Glaucoma:</strong></p><p>Hydrochlorothiazide, a sulfonamide, can cause an idiosyncratic reaction, resulting in acute transient myopia and acute angle-closure glaucoma. Symptoms include acute onset of decreased visual acuity or ocular pain and typically occur within hours to weeks of drug initiation. Untreated acute angle-closure glaucoma can lead to permanent vision loss. The primary treatment is to discontinue hydrochlorothiazide as rapidly as possible. Prompt medical or surgical treatments may need to be considered if the intraocular pressure remains uncontrolled. Risk factors for developing acute angle-closure glaucoma may include a history of sulfonamide or penicillin allergy.</p><p><strong>Ethnic differences:</strong></p><p>As with all other angiotensin II receptor antagonists, the blood pressure lowering effect of olmesartan medoxomil is somewhat less in black patients than in non-black patients, possibly because of a higher prevalence of low-renin status in the black hypertensive population.</p><p><strong>Anti-doping test:</strong></p><p>Hydrochlorothiazide contained in this medicinal product could produce a positive analytic result in an anti-doping test.</p><p><strong>Pregnancy:</strong></p><p>Angiotensin II receptor antagonists should not be initiated during pregnancy. Unless continued angiotensin II receptor antagonists therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started (see sections 4.3 and 4.6)</p><p><strong>Other:</strong></p><p>In general arteriosclerosis, in patients with ischaemic heart disease or ischaemic cerebrovascular disease, there is always a risk that excessive blood pressure decrease could result in a myocardial infarction or stroke.</p><p>Hypersensitivity reactions to hydrochlorothiazide may occur in patients with or without a history of allergy or bronchial asthma, but are more likely in patients with such a history.</p><p>Exacerbation or activation of systemic lupus erythematosus has been reported with the use of thiazide diuretics.</p><p>This medicinal product contains lactose. Patients with rare hereditary problems of galactose intolerance, the Lapp-lactase deficiency or glucose-galactose malabsorption should not take this medicinal product.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Potential interactions related to both olmesartan medoxomil and hydrochlorothiazide:</strong></p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>Lithium:</em></p><p>Reversible increases in serum lithium concentrations and toxicity have been reported during concomitant administration of lithium with angiotensin converting enzyme inhibitors and, rarely, with angiotensin II receptor antagonists. In addition, renal clearance of lithium is reduced by thiazides and consequently the risk of lithium toxicity may be increased. Therefore use of <strong>Olcontro<sup>&reg;</sup> HCT</strong> and lithium in combination is not recommended (see section 4.4). If use of the combination proves necessary, careful monitoring of serum lithium levels is recommended.</p><p><strong><em>Concomitant use requiring caution</em></strong></p><p><strong><em>Baclofen:</em></strong></p><p>Potentiation of antihypertensive effect may occur.</p><p><strong><em>Non-steroidal anti-inflammatory medicinal products:</em></strong></p><p>NSAIDs (i.e. acetylsalicylic acid (&gt; 3 g/day), COX-2 inhibitors and non-selective NSAIDs) may reduce the antihypertensive effect of thiazide diuretics and angiotensin II receptor antagonists.</p><p>In some patients with compromised renal function (e.g. dehydrated patients or elderly people with compromised renal function) the co-administration of angiotensin II receptor antagonists and agents that inhibit cyclo-oxygenase may result in further deterioration of renal function, including possible acute renal failure, which is usually reversible. Therefore, the combination should be administered with caution, especially in elderly people. Patients should be adequately hydrated and consideration should be given to monitoring of renal function after initiation of concomitant therapy and periodically thereafter.</p><p><strong><em>Concomitant use to be taken into account</em></strong></p><p><strong><em>Amifostine:</em></strong></p><p>Potentiation of antihypertensive effect may occur.</p><p><strong><em>Other antihypertensive agents:</em></strong></p><p>The blood pressure lowering effect of <strong>Olcontro<sup>&reg;</sup> HCT</strong> can be increased by concomitant use of other antihypertensive medicinal products.</p><p><strong><em>Alcohol, barbiturates, narcotics or antidepressants:</em></strong></p><p>Potentiation of orthostatic hypotension may occur.</p><p><strong>Potential interactions related to olmesartan medoxomil:</strong></p><p><strong><em>Concomitant use not recommended</em></strong></p><p><em>ACE-inhibitors, angiotensin II receptor blockers or aliskiren:</em></p><p>Clinical trial data has shown that dual blockade of the renin-angiotensin-aldosterone-system (RAAS) through the combined use of ACE-inhibitors, angiotensin II receptor blockers or aliskiren is associated with a higher frequency of adverse events such as hypotension, hyperkalaemia and decreased renal function (including acute renal failure) compared to the use of a single RAAS-acting agent (see sections 4.3, 4.4 and 5.1).</p><p><strong><em>Medicinal products affecting potassium levels:</em></strong></p><p>Based on experience with the use of other medicinal products that affect the renin-angiotensin system, concomitant use of potassium-sparing diuretics, potassium supplements, salt substitutes containing potassium or other medicinal products that may increase serum potassium levels (e.g. heparin, ACE inhibitors) may lead to increases in serum potassium (see section 4.4). If medicinal products which affect potassium levels are to be prescribed in combination with <strong>Olcontro<sup>&reg;</sup> HCT</strong>, monitoring of potassium plasma levels is advised.</p><p><strong><em>Bile acid sequestering agent colesevelam:</em></strong></p><p>Concurrent administration of the bile acid sequestering agent colesevelam hydrochloride reduces the systemic exposure and peak plasma concentration of olmesartan and reduces t1/2. Administration of olmesartan medoxomil at least 4 hours prior to colesevelam hydrochloride decreased the drug interaction effect. Administering olmesartan medoxomil at least 4 hours before the colesevelam hydrochloride dose should be considered (see section 5.2).</p><p><strong><em>Additional information</em></strong></p><p>After treatment with antacid (aluminium magnesium hydroxide), a modest reduction in bioavailability of olmesartan was observed.</p><p>Olmesartan medoxomil had no significant effect on the pharmacokinetics or pharmacodynamics of warfarin or the pharmacokinetics of digoxin.</p><p>Coadministration of olmesartan medoxomil with pravastatin had no clinically relevant effects on the pharmacokinetics of either component in healthy subjects.</p><p>Olmesartan had no clinically relevant inhibitory effects on human cytochrome P450 enzymes 1A1/2, 2A6, 2C8/9, 2C19, 2D6, 2E1 and 3A4&nbsp;<em>in vitro</em>, and had no or minimal inducing effects on rat cytochrome P450 activities. No clinically relevant interactions between olmesartan and medicinal products metabolised by the above cytochrome P450 enzymes are expected.</p><p><strong>Potential interactions related to hydrochlorothiazide</strong>:</p><p><strong><em>Concomitant use not recommended</em></strong></p><p><strong><em>Medicinal products affecting potassium levels:</em></strong></p><p>The potassium-depleting effect of hydrochlorothiazide (see section 4.4) may be potentiated by the coadministration of other medicinal products associated with potassium loss and hypokalaemia (e.g. other kaliuretic diuretics, laxatives, corticosteroids, ACTH, amphotericin, carbenoxolone, penicillin G sodium or salicylic acid derivatives). Such concomitant use is therefore not recommended.</p><p><strong><em>Concomitant use requiring caution</em></strong></p><p><strong><em>Calcium salts:</em></strong></p><p>Thiazide diuretics may increase serum calcium levels due to decreased excretion. If calcium supplements must be prescribed, serum calcium levels should be monitored and calcium dosage adjusted accordingly.</p><p><strong><em>Cholestyramine and colestipol resins:</em></strong></p><p>Absorption of hydrochlorothiazide is impaired in the presence of anionic exchange resins.</p><p><strong><em>Digitalis glycosides:</em></strong></p><p>Thiazide-induced hypokalaemia or hypomagnesaemia may favour the onset of digitalis-induced cardiac arrhythmias.</p><p><strong><em>Medicinal products affected by serum potassium disturbances:</em></strong></p><p>Periodic monitoring of serum potassium and ECG is recommended when <strong>Olcontro<sup>&reg;</sup> HCT</strong> is administered with medicinal products affected by serum potassium disturbances (e.g. digitalis glycosides and antiarrhythmics) and with the following torsades de pointes (ventricular tachycardia)-inducing medicinal products (including some antiarrhythmics), hypokalaemia being a predisposing factor to torsades de pointes (ventricular tachycardia):</p><p>&middot;&nbsp;&nbsp; Class Ia antiarrythmics (e.g. quinidine, hydroquinidine, disopyramide).</p><p>&middot;&nbsp;&nbsp; Class III antiarrythmics (e.g. amiodarone, sotalol, dofetilide, ibutilide).</p><p>&middot;&nbsp;&nbsp; Some antipsychotics (e.g. thioridazine, chlorpromazine, levomepromazine, trifluoperazine, cyamemazine, sulpiride, sultopride, amisulpride, tiapride, pimozide, haloperidol, droperidol).</p><p>&middot;&nbsp;&nbsp; Others (e.g. bepridil, cisapride, diphemanil, erythromycin IV, halofantrin, mizolastin, pentamidine, sparfloxacin, terfenadine, vincamine IV).</p><p><strong><em>Non-depolarizing skeletal muscle relaxants (e.g. tubocurarine):</em></strong></p><p>The effect of nondepolarizing skeletal muscle relaxants may be potentiated by hydrochlorothiazide.</p><p><strong><em>Anticholinergic agents (e.g. atropine, biperiden):</em></strong></p><p>Increase of the bioavailability of thiazide-type diuretics by decreasing gastrointestinal motility and stomach emptying rate.</p><p><strong><em>Antidiabetic medicinal products (oral agents and insulin):</em></strong></p><p>The treatment with a thiazide may influence the glucose tolerance. Dosage adjustment of the antidiabetic medicinal product may be required (see section 4.4).</p><p><strong><em>Metformin:</em></strong></p><p>Metformin should be used with caution because of the risk of lactic acidosis induced by possible functional renal failure linked to hydrochlorothiazide.</p><p><strong><em>Beta-blockers and diazoxide:</em></strong></p><p>The hyperglycaemic effect of beta-blockers and diazoxide may be enhanced by thiazides.</p><p><strong><em>Pressor amines (e.g. noradrenaline):</em></strong></p><p>The effect of pressor amines may be decreased.</p><p><strong><em>Medicinal products used in the treatment of gout (e.g. probenecid, sulfinpyrazone and allopurinol)</em></strong><strong>:</strong></p><p>Dosage adjustment of uricosuric medicinal products may be necessary since hydrochlorothiazide may raise the level of serum uric acid. Increase in dosage of probenecid or sulfinpyrazone may be necessary. Coadministration of a thiazide may increase the incidence of hypersensitivity reactions to allopurinol.</p><p><strong><em>Amantadine:</em></strong></p><p>Thiazides may increase the risk of adverse effects caused by amantadine.</p><p><strong><em>Cytotoxic agents (e.g. cyclophosphamide, methotrexate):</em></strong></p><p>Thiazides may reduce the renal excretion of cytotoxic medicinal products and potentiate their myelosuppressive effects.</p><p><strong><em>Salicylates:</em></strong></p><p>In case of high dosages of salicylates hydrochlorothiazide may enhance the toxic effect of the salicylates on the central nervous system.</p><p><strong><em>Methyldopa:</em></strong></p><p>There have been isolated reports of haemolytic anaemia occurring with concomitant use of hydrochlorothiazide and methyldopa.</p><p><strong><em>Cyclosporine:</em></strong></p><p>Concomitant treatment with cyclosporine may increase the risk of hyperuricaemia and gout-type complications.</p><p><strong><em>Tetracyclines:</em></strong></p><p>Concomitant administration of tetracyclines and thiazides increases the risk of tetracycline-induced increase in urea. This interaction is probably not applicable to doxycycline.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong><u>Pregnancy</u></strong></p><p>Given the effects of the individual components in this combination product on pregnancy, the use of <strong>Olcontro<sup>&reg;</sup> HCT</strong> is not recommended during the first trimester of pregnancy (see section 4.4). The use of <strong>Olcontro<sup>&reg;</sup> HCT</strong> is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p><strong><em>Olmesartan medoxomil:</em></strong></p><p>The use of angiotensin II receptor antagonists is not recommended during the first trimester of pregnancy (see section 4.4). The use of angiotensin II receptor antagonists is contra-indicated during the 2nd and 3rd trimester of pregnancy (see sections 4.3 and 4.4).</p><p>Epidemiological evidence regarding the risk of teratogenicity following exposure to ACE inhibitors during the first trimester of pregnancy has not been conclusive; however a small increase in risk cannot be excluded. Whilst there is no controlled epidemiological data on the risk with angiotensin II receptor antagonists, similar risks may exist for this class of drugs. Unless continued angiotensin receptor blocker therapy is considered essential, patients planning pregnancy should be changed to alternative anti-hypertensive treatments which have an established safety profile for use in pregnancy. When pregnancy is diagnosed, treatment with angiotensin II receptor antagonists should be stopped immediately, and, if appropriate, alternative therapy should be started.</p><p>Exposure to angiotensin II receptor antagonists therapy during the 2nd and 3rd trimesters is known to induce human fetotoxicity (decreased renal function, oligohydramnios, skull ossification retardation) and neonatal toxicity (renal failure, hypotension, hyperkalaemia). (See also 5.3 &ldquo;Preclinical safety data&rdquo;.)</p><p>Should exposure to angiotensin II receptor antagonists have occurred from the 2nd trimester of pregnancy, ultrasound check of renal function and skull is recommended.</p><p>Infants whose mothers have taken angiotensin II receptor antagonists should be closely observed for hypotension (see also sections 4.3 and 4.4).</p><p><strong><em>Hydrochlorothiazide:</em></strong></p><p>There is limited experience with hydrochlorothiazide during pregnancy, especially during the first trimester. Animal studies are insufficient.</p><p>Hydrochlorothiazide crosses the placenta. Based on the pharmacological mechanism of action of hydrochlorothiazide its use during the 2nd and 3rd trimester may compromise foeto-placental perfusion and may cause foetal and neonatal effects like icterus, disturbance of electrolyte balance and thrombocytopenia.</p><p>Hydrochlorothiazide should not be used for gestational oedema, gestational hypertension or preeclampsia due to the risk of decreased plasma volume and placental hypoperfusion, without a beneficial effect on the course of the disease.</p><p>Hydrochlorothiazide should not be used for essential hypertension in pregnant women except in rare situations where no other treatment could be used.</p><p><strong><u>Breast-feeding</u></strong></p><p><strong><em>Olmesartan medoxomil:</em></strong></p><p>Because no information is available regarding the use of Olmesartan medoxomil/ hydrochlorothiazide during breast-feeding, <strong>Olcontro<sup>&reg;</sup> HCT</strong> is not recommended and alternative treatments with better established safety profiles during breast-feeding are preferable, especially while nursing a newborn or preterm infant.</p><p><strong><em>Hydrochlorothiazide:</em></strong></p><p>Hydrochlorothiazide is excreted in human milk in small amounts. Thiazides in high doses causing intense diuresis can inhibit the milk production.</p><p>The use of <strong>Olcontro<sup>&reg;</sup> HCT</strong> during breast-feeding is not recommended. If <strong>Olcontro<sup>&reg;</sup> HCT</strong> is used during breast-feeding, doses should be kept as low as possible.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Olcontro<sup>&reg;</sup> HCT</strong> has minor or moderate influence on the ability to drive and use machines. Dizziness or fatigue may occasionally occur in patients taking antihypertensive therapy, which may impair the ability to react.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The most commonly reported adverse reactions during treatment with olmesartan medoxomil/hydrochlorothiazide are headache (2.9%), dizziness (1.9%) and fatigue (1.0%).</p><p>Hydrochlorothiazide may cause or exacerbate volume depletion which may lead to electrolyte imbalance (see section 4.4).</p><p>In clinical trials involving 1155 patients treated with olmesartan medoxomil/ hydrochlorothiazide combinations at dosages of 20/12.5 mg or 20/25 mg and 466 patients treated with placebo for periods of up to 21 months, the overall frequency of adverse reactions on olmesartan medoxomil/hydrochlorothiazide combination therapy was similar to that on placebo. Discontinuations due to adverse reactions were also similar for olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg - 20/25 mg (2%) and placebo (3%). The frequency of adverse reactions on olmesartan medoxomil/ hydrochlorothiazide overall relative to placebo appeared to be unrelated to age (&lt; 65 years versus &ge; 65 years), gender or race although the frequency of dizziness was somewhat increased in patients aged &ge; 75 years.</p><p>In addition, the safety of combination as a high dose olmesartan medoxomil/hydrochlorothiazide combination was investigated in clinical trials in 3709 patients receiving olmesartan medoxomil in combination with hydrochlorothiazide in the dose strengths 40/12.5 mg and 40/25 mg.</p><p>Adverse reactions from olmesartan medoxomil/hydrochlorothiazide combination in clinical trials, post-authorisation safety studies and spontaneous reporting are summarised in the below table as well as adverse reactions from the individual components olmesartan medoxomil and hydrochlorothiazide based on the known safety profile of these substances.</p><p>The following terminologies have been used in order to classify the occurrence of adverse reactions: very common (&ge;1/10); common (&ge;1/100 to &lt;1/10); uncommon (&ge;1/1,000 to &lt;1/100); rare (&ge;1/10,000 to &lt;1/1,000); very rare (&lt;1/10,000), not known (cannot be estimated from the available data).</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td rowspan="2" style="vertical-align:top"><p><strong>MedDRA</strong></p><p><strong>System Organ Class</strong></p></td><td rowspan="2" style="vertical-align:top"><p><strong>Adverse reactions</strong></p></td><td colspan="3" style="vertical-align:top"><p><strong>Frequency</strong></p></td></tr><tr><td style="vertical-align:top"><p><strong>Combination</strong></p></td><td style="vertical-align:top"><p><strong>Olmesartan</strong></p></td><td style="vertical-align:top"><p><strong>HCTZ</strong></p></td></tr><tr><td style="vertical-align:top"><p>Infections and infestations</p></td><td style="vertical-align:top"><p>Sialadenitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Blood and lymphatic system disorders</p></td><td style="vertical-align:top"><p>Aplastic anaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Bone marrow depression</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Haemolytic anaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Leukopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Neutropenia/ Agranulocytosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Thrombocytopenia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Immune system disorders</p></td><td style="vertical-align:top"><p>Anaphylactic reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Metabolism and nutrition disorders</p></td><td style="vertical-align:top"><p>Anorexia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Glykosuria</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercalcaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypercholesterolaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperglycaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperkalaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hypertriglyceridaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperuricaemia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Very common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypochloraemic alcalosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypokaliaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hypomagnesaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyponatriaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Hyperamylasaemia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td rowspan="4" style="vertical-align:top"><p>Psychiatric disorders</p></td><td style="vertical-align:top"><p>Apathy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Depression</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Restlessness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Sleep disturbances</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="10" style="vertical-align:top"><p>Nervous system disorders</p></td><td style="vertical-align:top"><p>Confusional state</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Convulsions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Disturbances in consciousness (such as loss of consciousness)</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dizziness/light-headedness</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Loss of appetite</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Paraesthesia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Postural dizziness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Somnolence</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Syncope</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Eye disorders</p></td><td style="vertical-align:top"><p>Lacrimation decreased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Transient blurred vision</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Worsening of pre-existing myopia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Acute myopia, acute angle-closure glaucoma</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Not known</p></td></tr><tr><td style="vertical-align:top"><p>Xanthopsia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Ear and labyrinth disorders</p></td><td style="vertical-align:top"><p>Vertigo</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="3" style="vertical-align:top"><p>Cardiac disorders</p></td><td style="vertical-align:top"><p>Angina pectoris</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cardiac arrhythmias</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Palpitations</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="5" style="vertical-align:top"><p>Vascular disorders</p></td><td style="vertical-align:top"><p>Embolism</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Necrotising angiitis (vasculitis, cutaneous vasculitis)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Orthostatic hypotension</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Thrombosis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="8" style="vertical-align:top"><p>Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top"><p>Bronchitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cough</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Dyspnoea</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Interstitial pneumonia</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Pharyngitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Pulmonary oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Respiratory distress</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rhinitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="12" style="vertical-align:top"><p>Gastrointestinal disorders</p></td><td style="vertical-align:top"><p>Abdominal pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Constipation</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Dyspepsia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gastric irritation</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Gastroenteritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Meteorism</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Nausea</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Pancreatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Paralytic ileus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td></tr><tr><td style="vertical-align:top"><p>Vomiting</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Sprue-like enteropathy (see section 4.4)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Very rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="2" style="vertical-align:top"><p>Hepato-biliary disorders</p></td><td style="vertical-align:top"><p>Acute cholecystitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Jaundice (intrahepatic cholestasic icterus)</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td rowspan="14" style="vertical-align:top"><p>Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top"><p>Allergic dermatitis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Anaphylactic skin reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Angioneurotic oedema</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Cutaneous lupus erythematodes-like reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Eczema</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Erythema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Exanthem</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Photosensitivity reactions</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Pruritus</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Purpura</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Rash</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td style="vertical-align:top"><p>Reactivation of cutaneous lupus erythematodes</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Toxic epidermal necrolysis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urticaria</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="9" style="vertical-align:top"><p>Musculoskeletal and connective tissue disorders</p></td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Arthritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Back pain</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Muscle spasm</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Muscular weakness</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Myalgia</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Pain in extremity</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Paresis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Skeletal pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="6" style="vertical-align:top"><p>Renal and urinary disorders</p></td><td style="vertical-align:top"><p>Acute renal failure</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Haematuria</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Interstitial nephritis</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Renal insufficiency</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Renal dysfunction</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Urinary tract infection</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Reproductive system and breast disorders</p></td><td style="vertical-align:top"><p>Erectile dysfunction</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td></tr><tr><td rowspan="11" style="vertical-align:top"><p>General disorders and administration site conditions</p></td><td style="vertical-align:top"><p>Asthenia</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Chest pain</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Face oedema</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fatigue</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Fever</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td></tr><tr><td style="vertical-align:top"><p>Influenza-like symptoms</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Lethargy</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Malaise</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Pain</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Peripheral oedema</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Weakness</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td rowspan="16" style="vertical-align:top"><p>Investigations</p></td><td style="vertical-align:top"><p>Alanine aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Aspartate aminotransferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood calcium increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood creatinine increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood creatine phosphokinase increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood glucose increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood haematocrit decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood haemoglobin decreased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood lipids increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood potassium decreased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood potassium increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood urea increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top"><p>Common</p></td></tr><tr><td style="vertical-align:top"><p>Blood urea nitrogen increased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Blood uric acid increased</p></td><td style="vertical-align:top"><p>Rare</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Gamma glutamyl transferase increased</p></td><td style="vertical-align:top"><p>Uncommon</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td></tr><tr><td style="vertical-align:top"><p>Hepatic enzymes increased</p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Common</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p>Single cases of rhabdomyolysis have been reported in temporal association with the intake of angiotensin II receptor blockers.</p><p><u>&nbsp;</u></p><p><strong>To report any side effect(s):</strong></p><p><strong>&bull; Saudi Arabia:</strong></p><p>The National Pharmacovigilance Center (NPC):</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p><p><strong>&bull; Other GCC States:</strong></p><p>Please contact the relevant competent authority.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No specific information is available on the effects or treatment of olmesartan medoxomil/ hydrochlorothiazide overdose. The patient should be closely monitored, and the treatment should be symptomatic and supportive. Management depends upon the time since ingestion and the severity of the symptoms. Suggested measures include induction of emesis and/or gastric lavage. Activated charcoal may be useful in the treatment of overdose. Serum electrolytes and creatinine should be monitored frequently. If hypotension occurs, the patient should be placed in a supine position, with salt and volume replacements given quickly.</p><p>The most likely manifestations of olmesartan medoxomil overdose are expected to be hypotension and tachycardia; bradycardia might also occur. Overdose with hydrochlorothiazide is associated with electrolyte depletion (hypokalaemia, hypochloraemia) and dehydration resulting from excessive diuresis. The most common signs and symptoms of overdose are nausea and somnolence. Hypokalaemia may result in muscle spasm and/or accentuate cardiac arrhythmias associated with the concomitant use of digitalis glycosides or certain anti-arrhythmic medicinal products.</p><p>No information is available regarding the dialysability of olmesartan or hydrochlorothiazide.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Angiotensin II antagonists, ATC code: C09C A 08.</p><p><strong><u>Mechanism of action / Pharmacodynamic effects</u></strong></p><p><strong>Olcontro<sup>&reg;</sup> HCT</strong> is a combination of an angiotensin II receptor antagonist, olmesartan medoxomil, and a thiazide diuretic, hydrochlorothiazide. The combination of these ingredients has an additive antihypertensive effect, reducing blood pressure to a greater degree than either component alone.</p><p>Once daily dosing with <strong>Olcontro<sup>&reg;</sup> HCT</strong> provides an effective and smooth reduction in blood pressure over the 24 hour dose interval.</p><p><strong>Olmesartan medoxomil</strong> is a potent, orally active, selective angiotensin II receptor (type AT<sub>1</sub>) antagonist. It is expected to block all actions of angiotensin II mediated by the AT<sub>1&nbsp;</sub>receptor, regardless of the source or route of synthesis of angiotensin II. The selective antagonism of the angiotensin II (AT<sub>1</sub>) receptors results in increases in plasma renin levels and angiotensin I and II concentrations, and some decrease in plasma aldosterone concentrations.</p><p>Angiotensin II is the primary vasoactive hormone of the renin-angiotensin-aldosterone system and plays a significant role in the pathophysiology of hypertension via the type 1 (AT<sub>1</sub>) receptor.</p><p><u>Clinical efficacy and safety</u></p><p>In hypertension, olmesartan medoxomil causes a dose-dependent, long-lasting reduction in arterial blood pressure. There has been no evidence of first-dose hypotension, of tachyphylaxis during long-term treatment, or of rebound hypertension after cessation of therapy.</p><p>Once daily dosing with olmesartan medoxomil provides an effective and smooth reduction in blood pressure over the 24 hour dose interval. Once daily dosing produced similar decreases in blood pressure as twice daily dosing at the same total daily dose.</p><p>With continuous treatment, maximum reductions in blood pressure are achieved by 8 weeks after the initiation of therapy, although a substantial proportion of the blood pressure lowering effect is already observed after 2 weeks of treatment. When used together with hydrochlorothiazide, the reduction in blood pressure is additive and coadministration is well tolerated.</p><p>The effect of olmesartan on mortality and morbidity is not yet known.</p><p>The Randomised Olmesartan and Diabetes Microalbuminuria Prevention (ROADMAP) study in 4447 patients with type 2 diabetes, normo-albuminuria and at least one additional cardiovascular risk factor, investigated whether treatment with olmesartan could delay the onset of microalbuminuria. During the median follow-up duration of 3.2 years, patients received either olmesartan or placebo in addition to other antihypertensive agents, except ACE inhibitors or ARBs.</p><p>For the primary endpoint, the study demonstrated a significant risk reduction in the time to onset of microalbuminuria, in favour of olmesartan. After adjustment for BP differences this risk reduction was no longer statistically significant. 8.2% (178 of 2160) of the patients in the olmesartan group and 9.8% (210 of 2139) in the placebo group developed microalbuminuria.</p><p>For the secondary endpoints, cardiovascular events occurred in 96 patients (4.3%) with olmesartan and in 94 patients (4.2%) with placebo. The incidence of cardiovascular mortality was higher with olmesartan compared to placebo treatment (15 patients (0.7%) vs. 3 patients (0.1%)), despite similar rates for non-fatal stroke (14 patients (0.6%) vs. 8 patients (0.4%)), non-fatal myocardial infarction (17 patients (0.8%) vs. 26 patients (1.2%)) and non-cardiovascular mortality (11 patients (0.5%) vs. 12 patients (0.5%)). Overall mortality with olmesartan was numerically increased (26 patients (1.2%) vs. 15 patients (0.7%)), which was mainly driven by a higher number of fatal cardiovascular events.</p><p>The Olmesartan Reducing Incidence of End-stage Renal Disease in Diabetic Nephropathy Trial (ORIENT) investigated the effects of olmesartan on renal and cardiovascular outcomes in 577 randomized Japanese and Chinese type 2 diabetic patients with overt nephropathy. During a median follow-up of 3.1 years, patients received either olmesartan or placebo in addition to other antihypertensive agents including ACE inhibitors.</p><p>The primary composite endpoint (time to first event of the doubling of serum creatinine, end-stage renal disease, all-cause death) occurred in 116 patients in the olmesartan group (41.1%) and 129 patients in the placebo group (45.4%) (HR 0.97 (95% CI 0.75 to 1.24); p=0.791). The composite secondary cardiovascular endpoint occurred in 40 olmesartan-treated patients (14.2%) and 53 placebo-treated patients (18.7%). This composite cardiovascular endpoint included cardiovascular death in 10 (3.5%) patients receiving olmesartan versus 3 (1.1%) receiving placebo, overall mortality 19 (6.7%) versus 20 (7.0%), non-fatal stroke 8 (2.8%) versus 11 (3.9%) and non-fatal myocardial infarction 3 (1.1%) versus 7 (2.5%), respectively.</p><p><u>Hydrochlorothiazide</u>&nbsp;is a thiazide diuretic. The mechanism of the antihypertensive effect of thiazide diuretics is not fully known. Thiazides affect the renal tubular mechanisms of electrolyte reabsorption, directly increasing excretion of sodium and chloride in approximately equivalent amounts. The diuretic action of hydrochlorothiazide reduces plasma volume, increases plasma renin activity and increases aldosterone secretion, with consequent increases in urinary potassium and bicarbonate loss, and decreases in serum potassium. The renin-aldosterone link is mediated by angiotensin II and therefore coadministration of an angiotensin II receptor antagonist tends to reverse the potassium loss associated with thiazide diuretics. With hydrochlorothiazide, onset of diuresis occurs at about 2 hours and peak effect occurs at about 4 hours post-dose, whilst the action persists for approximately 6-12 hours.</p><p>Epidemiological studies have shown that long-term treatment with hydrochlorothiazide monotherapy reduces the risk of cardiovascular mortality and morbidity.</p><p><u>Clinical efficacy and safety</u></p><p><u>The combination of olmesartan medoxomil and hydrochlorothiazide</u>&nbsp;produces additive reductions in blood pressure which generally increase with the dose of each component.</p><p>In pooled placebo-controlled studies, administration of the 20/12.5 mg and 20/25 mg combinations of olmesartan medoxomil/hydrochlorothiazide resulted in mean placebo-subtracted systolic/diastolic blood pressure reductions at trough of 12/7 mmHg and 16/9 mmHg, respectively.</p><p>Administration of 12.5 mg and 25 mg hydrochlorothiazide in patients insufficiently controlled by olmesartan medoxomil 20 mg monotherapy gave additional reductions in 24-hour systolic/diastolic blood pressures measured by ambulatory blood pressure monitoring of 7/5 mmHg and 12/7 mmHg, respectively, compared with olmesartan medoxomil monotherapy. The additional mean systolic/diastolic blood pressure reductions at trough compared with baseline were 11/10 mmHg and 16/11 mmHg, respectively.</p><p>The effectiveness of olmesartan medoxomil/hydrochlorothiazide combination therapy was maintained over long-term (one-year) treatment. Withdrawal of olmesartan medoxomil therapy, with or without concomitant hydrochlorothiazide therapy, did not result in rebound hypertension.</p><p>The fixed combinations of olmesartan medoxomil and hydrochlorothiazide 40/12.5 mg and 40/25 mg were investigated in three clinical studies including 1482 hypertensive patients.</p><p>A double-blind study with essential hypertension evaluated the effectiveness of olmesartan medoxomil/hydrochlorothiazide 40/12.5 mg combination therapy versus olmesartan medoxomil monotherapy 40 mg with mean sitting diastolic blood pressure reduction being the primary efficacy parameter. Systolic/diastolic blood pressure was reduced by 31.9/18.9 mmHg in the combination group as compared to 26.5/15.8 in the monotherapy group (p&lt;0.0001) after 8 weeks of treatment.</p><p>In a double-blind but non-controlled second phase of this study, up-titration of non-responders from olmesartan medoxomil monotherapy (olmesartan medoxomil) 40 mg to olmesartan medoxomil/hydrochlorothiazide 40/12.5 mg as well as from olmesartan medoxomil/hydrochlorothiazide 40/12.5 mg to olmesartan medoxomil/ hydrochlorothiazide&nbsp; 40/25 mg resulted in a further relevant decrease in systolic/diastolic blood pressure, thus confirming that up-titration is a clinically meaningful way to improve blood pressure control.</p><p>A second double-blind, randomised, placebo-controlled study evaluated the effectiveness of adding hydrochlorothiazide to the treatment of patients not adequately controlled after 8 weeks of treatment with olmesartan 40 mg. Patients either continued on olmesartan 40 mg or received additional hydrochlorothiazide 12.5mg or 25mg respectively for another 8 weeks. A fourth group was randomised to receive olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg.</p><p>Adding hydrochlorothiazide 12.5 mg or 25 mg resulted in a further reduction in systolic/diastolic blood pressure of 5.2/3.4 mmHg (p &lt; 0.0001) and 7.4/5.3 mmHg (p &lt; 0.0001) respectively as compared to the olmesartan 40 mg therapy alone.</p><p>A comparison between patients receiving olmesartan medoxomil/hydrochlorothiazide 20/12.5 mg and patients receiving 40/12.5 mg showed a statistical significant difference in systolic blood pressure reduction of 2.6 mmHg in favour of the higher dose combination (p=0.0255) whereas for diastolic blood pressure reduction a difference of 0.9 mmHg was observed. Ambulatory blood pressure monitoring (ABPM) based on the mean changes on 24-hour, daytime and night-time diastolic and systolic blood pressure data confirmed the results of conventional blood pressure measures.</p><p>Another double-blind, randomised trial compared the effectiveness of a combination treatment with olmesartan medoxomil/hydrochlorothiazide 20/25 mg and olmesartan medoxomil/hydrochlorothiazide 40/25 mg in patients with inadequately controlled blood pressure after 8 weeks of treatment with olmesartan 40 mg.</p><p>After 8 weeks of combination therapy the systolic/diastolic blood pressure was significantly reduced as compared to baseline by 17.1/10.5 mmHg in the olmesartan medoxomil/hydrochlorothiazide 20/25 mg group and 17.4/11.2 mmHg in the olmesartan medoxomil/hydrochlorothiazide 40/25 mg group. The difference between both treatment groups was not statistically significant when using conventional blood pressure measurement, which might be explained by the known flat dose response effect of angiotensin II receptor antagonists such as Olmesartan medoxomil.</p><p>However, a clinically meaningful and statistically significant difference in favour of olmesartan medoxomil/hydrochlorothiazide 40/25 mg as compared to olmesartan medoxomil/hydrochlorothiazide 20/25 mg was observed in mean 24-hour, daytime and night-time ABPM on both systolic and diastolic blood pressure.</p><p>The antihypertensive effect of olmesartan medoxomil/hydrochlorothiazide was similar irrespective of age, gender or diabetes status.</p><p><u>Other information:</u></p><p>Two large randomised, controlled trials (ONTARGET (ONgoing Telmisartan Alone and in combination with Ramipril Global Endpoint Trial) and VA NEPHRON-D (The Veterans Affairs Nephropathy in Diabetes)) have examined the use of the combination of an ACE-inhibitor with an angiotensin II receptor blocker.</p><p>ONTARGET was a study conducted in patients with a history of cardiovascular or cerebrovascular disease, or type 2 diabetes mellitus accompanied by evidence of end-organ damage. VA NEPHRON-D was a study in patients with type 2 diabetes mellitus and diabetic nephropathy.</p><p>These studies have shown no significant beneficial effect on renal and/or cardiovascular outcomes and mortality, while an increased risk of hyperkalaemia, acute kidney injury and/or hypotension as compared to monotherapy was observed. Given their similar pharmacodynamic properties, these results are also relevant for other ACE-inhibitors and angiotensin II receptor blockers.</p><p>ACE-inhibitors and angiotensin II receptor blockers should therefore not be used concomitantly in patients with diabetic nephropathy.</p><p>ALTITUDE (Aliskiren Trial in Type 2 Diabetes Using Cardiovascular and Renal Disease Endpoints) was a study designed to test the benefit of adding aliskiren to a standard therapy of an ACE-inhibitor or an angiotensin II receptor blocker in patients with type 2 diabetes mellitus and chronic kidney disease, cardiovascular disease, or both. The study was terminated early because of an increased risk of adverse outcomes. Cardiovascular death and stroke were both numerically more frequent in the aliskiren group than in the placebo group and adverse events and serious adverse events of interest (hyperkalaemia, hypotension and renal dysfunction) were more frequently reported in the aliskiren group than in the placebo group.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption and distribution</u></p><p><em>Olmesartan medoxomil:</em></p><p>Olmesartan medoxomil is a prodrug. It is rapidly converted to the pharmacologically active metabolite, olmesartan, by esterases in the gut mucosa and in portal blood during absorption from the gastrointestinal tract. No intact olmesartan medoxomil or intact side chain medoxomil moiety have been detected in plasma or excreta. The mean absolute bioavailability of olmesartan from a tablet formulation was 25.6%.</p><p>The mean peak plasma concentration (C<sub>max</sub>) of olmesartan is reached within about 2 hours after oral dosing with olmesartan medoxomil, and olmesartan plasma concentrations increase approximately linearly with increasing single oral doses up to about 80 mg.</p><p>Food had minimal effect on the bioavailability of olmesartan and therefore olmesartan medoxomil may be administered with or without food.</p><p>No clinically relevant gender-related differences in the pharmacokinetics of olmesartan have been observed.</p><p>Olmesartan is highly bound to plasma protein (99.7%), but the potential for clinically significant protein binding displacement interactions between olmesartan and other highly bound coadministered active substances is low (as confirmed by the lack of a clinically significant interaction between olmesartan medoxomil and warfarin). The binding of olmesartan to blood cells is negligible. The mean volume of distribution after intravenous dosing is low (16 &ndash; 29 L).</p><p><em>Hydrochlorothiazide:</em></p><p>Following oral administration of olmesartan medoxomil and hydrochlorothiazide in combination, the median time to peak concentrations of hydrochlorothiazide was 1.5 to 2 hours after dosing. Hydrochlorothiazide is 68 % protein bound in the plasma and its apparent volume of distribution is 0.83 &ndash; 1.14 L/kg.</p><p><u>Biotransformation and elimination</u></p><p><em>Olmesartan medoxomil:</em></p><p>Total plasma clearance of olmesartan was typically 1.3 L/h (CV, 19%) and was relatively slow compared to hepatic blood flow (ca 90 L/h). Following a single oral dose of&nbsp;<sup>14</sup>C-labelled olmesartan medoxomil, 10 - 16% of the administered radioactivity was excreted in the urine (the vast majority within 24 hours of dose administration) and the remainder of the recovered radioactivity was excreted in the faeces. Based on the systemic availability of 25.6%, it can be calculated that absorbed olmesartan is cleared by both renal excretion (ca 40%) and hepato-biliary excretion (ca 60%). All recovered radioactivity was identified as olmesartan. No other significant metabolite was detected. Enterohepatic recycling of olmesartan is minimal. Since a large proportion of olmesartan is excreted via the biliary route, use in patients with biliary obstruction is contraindicated (see section 4.3).</p><p>The terminal elimination half life of olmesartan varied between 10 and 15 hours after multiple oral dosing. Steady state was reached after the first few doses and no further accumulation was evident after 14 days of repeated dosing. Renal clearance was approximately 0.5 &ndash; 0.7 L/h and was independent of dose.</p><p><em>Hydrochlorothiazide:</em></p><p>Hydrochlorothiazide is not metabolised in man and is excreted almost entirely as unchanged active substance in urine. About 60 % of the oral dose is eliminated as unchanged active substance within 48 hours. Renal clearance is about 250 &ndash; 300 mL/min. The terminal elimination half-life of hydrochlorothiazide is 10 &ndash; 15 hours.</p><p>Olmesartan medoxomil/hydrochlorothiazide</p><p>The systemic availability of hydrochlorothiazide is reduced by about 20% when co-administered with olmesartan medoxomil, but this modest decrease is not of any clinical relevance. The kinetics of olmesartan are unaffected by the co-administration of hydrochlorothiazide.</p><p><u>Pharmacokinetics in special populations</u></p><p><em>Elderly (age 65 years or over)</em>:</p><p>In hypertensive patients, the olmesartan AUC at steady state was increased by ca 35% in elderly people (65 &ndash; 75 years old) and by ca 44% in very elderly people (&ge; 75 years old) compared with the younger age group (see section 4.2).</p><p>Limited data suggest that the systemic clearance of hydrochlorothiazide is reduced in both healthy and hypertensive elderly people compared to young healthy volunteers.</p><p><em>Renal impairment:</em></p><p>In renally impaired patients, the olmesartan AUC at steady state increased by 62%, 82% and 179% in patients with mild, moderate and severe renal impairment, respectively, compared to healthy controls (see sections 4.2, 4.3, 4.4).</p><p>The maximum dose of olmesartan medoxomil in patients with mild to moderate renal impairment (creatinine clearance of 30 &ndash; 60 mL/min) is 20 mg olmesartan medoxomil once daily. The use of olmesartan medoxomil in patients with severe renal impairment (creatinine clearance of &lt; 30 mL/min) is not recommended.</p><p>The half-life of hydrochlorothiazide is prolonged in patients with impaired renal function.</p><p><em>Hepatic impairment:</em></p><p>After single oral administration, olmesartan AUC values were 6% and 65% higher in mildly and moderately hepatically impaired patients, respectively, than in their corresponding matched healthy controls. The unbound fraction of olmesartan at 2 hours post-dose in healthy subjects, in patients with mild hepatic impairment and in patients with moderate hepatic impairment was 0.26%, 0.34% and 0.41%, respectively. Following repeated dosing in patients with moderate hepatic impairment, olmesartan mean AUC was again about 65% higher than in matched healthy controls. Olmesartan mean C<sub>max</sub>&nbsp;values were similar in hepatically-impaired and healthy subjects.</p><p>In patients with moderate hepatic impairment, an initial dose of 10 mg olmesartan medoxomil once daily is recommended and the maximum dose should not exceed 20 mg once daily. Olmesartan medoxomil has not been evaluated in patients with severe hepatic impairment (see sections 4.2, 4.3, 4.4).</p><p>Hepatic impairment does not significantly influence the pharmacokinetics of hydrochlorothiazide<strong><em>.</em></strong></p><p><strong>Drug interactions</strong></p><p><em>Bile acid sequestering agent colesevelam:</em></p><p>Concomitant administration of 40 mg olmesartan medoxomil and 3750 mg colesevelam hydrochloride in healthy subjects resulted in 28% reduction in C<sub>max</sub>&nbsp;and 39% reduction in AUC of olmesartan. Lesser effects, 4% and 15% reduction in C<sub>max</sub>&nbsp;and AUC respectively, were observed when olmesartan medoxomil was administered 4 hours prior to colesevelam hydrochloride. Elimination half life of olmesartan was reduced by 50 &ndash; 52% irrespectively of whether administered concomitantly or 4 hours prior to colesevelam hydrochloride (see section 4.5).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The toxic potential of olmesartan medoxomil/hydrochlorothiazide combinations was evaluated in repeated dose oral toxicity studies for up to six months in rats and dogs.</p><p>As for each of the individual substances and other medicinal products in this class, the main toxicological target organ of the combination was the kidney. The combination of olmesartan medoxomil/hydrochlorothiazide induced functional renal changes (increases in serum urea nitrogen and in serum creatinine). High dosages caused tubular degeneration and regeneration in the kidneys of rats and dogs, probably via a change in renal haemodynamics (reduced renal perfusion resulting from hypotension with tubular hypoxia and tubular cell degeneration). In addition the olmesartan medoxomil/ hydrochlorothiazide combination caused a decrease in red blood cell parameters (erythrocytes, haemoglobin and haematocrit) and a reduction in heart weight in rats.</p><p>These effects have also been observed for other AT<sub>1</sub>&nbsp;receptor antagonists and for ACE inhibitors and they seem to have been induced by the pharmacological action of high dosages of olmesartan medoxomil and seem to be not relevant to humans at the recommended therapeutic doses.</p><p>Genotoxicity studies using combined olmesartan medoxomil and hydrochlorothiazide as well as the individual components have not shown any signs of a clinically relevant genotoxic activity.</p><p>The carcinogenic potential of a combination of olmesartan medoxomil and hydrochlorothiazide was not investigated as there was no evidence of relevant carcinogenic effects for the two individual components under conditions of clinical use.</p><p>There was no evidence of teratogenicity in mice or rats treated with olmesartan medoxomil/hydrochlorothiazide combinations. As expected from this class of medicinal product, foetal toxicity was observed in rats, as evidenced by significantly reduced foetal body weights, when treated with olmesartan medoxomil/hydrochlorothiazide combinations during gestation (see sections 4.3, 4.6).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate, microcrystalline cellulose, sodium starch glycolate, hydroxypropyl cellulose, colloidal silicon dioxide, magnesium stearate, Hypromellose, talc, titanium dioxide, iron oxide red, purified water.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <table border="0" cellpadding="0"><tbody><tr><td><p>None.</p></td></tr></tbody></table>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                24 months.
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Olcontro<sup>&reg; </sup>HCT</strong><strong> 20/12.5 mg: </strong>Reddish- yellow, round, biconvex, film-coated tablets debossed with &lsquo;M 11&rsquo; on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 28 Film Coated tablets.</p><p><strong>&nbsp;</strong></p><p><strong>Olcontro<sup>&reg; </sup>HCT</strong><strong> 40/12.5 mg: </strong>Reddish-yellow, oval, biconvex, film-coated tablets debossed with &lsquo;M 13&rsquo; on one side and plain on other side, presented in Alu/Alu blisters, intended for oral use.</p><p><strong>Pack size:</strong> 28 Film Coated tablets.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Med City Pharma - KSA
Tel: 00966920003288
Fax: 00966126358138
Mobile: 00966555786968
P.O .Box: 42512 - Jeddah 21551
E-mail: MD.admin@axantia.com
Manufacturer:               
Macleods Pharmaceuticals Limited – India. 
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                08/2021
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>